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EFFECT OF ENTINOSTAT ON NK CELL-MEDIATED CYTOTOXICITY
AGAINST OS CELLS AND OS LUNG METASTSIS

Simin Kiany, MS
Advisory Professor: Eugenie S. Kleinerman, M.D.

The purpose of this study was to investigate the effect of the HDAC inhibitor
entinostat on the efficacy of NK cell therapy for OS lung metastasis. The Lung is
the most common site of OS metastatic spread in OS and pulmonary metastasis
is the main cause of mortality. We have previously demonstrated that NK cell
therapy has minimal efficacy against OS metastasis. We wished to determine
whether we could augment the killing of OS cells in vitro and improve the efficacy
of NK cell therapy in vivo by adding oral administration of entinostat. We elected
to use our nude mouse human OS lung metastasis model for this purpose. In vitro,
entinostat increased NK cell ligands on OS cells (MIC A/B, ULBP1, ULBP2/5/6,
and CD155) and enhanced the NK cell-mediated cytotoxicity. Entinostat oral
administration also increased MICA/B expression on lung tumors. Entinostat (≤ 2
μM) did not have any adverse effect on NK cell viability, receptor expression, or
function within the 24 h treatment.
We demonstrated two potential mechanisms by which entinostat enhanced
expression of MICA and MICB. Our data showed that entinostat increased the
acetylation of histone 4 on the MICA and MICB gene promoters which enhanced
MICA and MICB gene transcription. We also showed that entinostat decreased the
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expression of mir-20a, mir-93, and mir-106b, microRNAs that up-regulate both
MICA and MICB.
Although our findings showed that entinostat augmented NK cell-mediated
cytotoxicity against OS cells in vitro, the in vivo studies failed to show enhanced
efficacy of the combination therapy. This may be explained by our finding that while
NK cells infiltrated into the lungs and were at the tumor periphery, we were unable
to detect the presence of NK cells inside lung tumors. This suggests that adding a
cytokine such as IL-2 and IL-21 may enhance the NK cells trafficking into the lung
nodules and improve the NK cell therapy efficacy. Entinostat up-regulated the
immune inhibitory molecule PD-L1 on OS cells. Therefore, blocking PD/PDL1
interaction by PD-L1 monoclonal antibody may increase the anti-tumor effect of
entinostat+ NK cells. Further investigations are necessary to define the specific
mechanism of resistance.
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INTRODUCTION

Chapter 1
Introduction: background, rationale and research plan
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Osteosarcoma
Osteosarcoma (OS) is the most common primary bone tumor that originates
from transformed mesenchymal stem cells. OS occurs in both children and adults
with two peaks of incidence, one at the age of 10-14 years, and the second at age
of 65 and older. The survival rate of OS patients is inversely correlated with their
age and older patients have a worse prognosis (1). Based on the National Cancer
Institute SEER report, the incidence of OS is more frequent in the African American
and Hispanic population than in the white population. Although OS can be
diagnosed in any bone, the most common sites of occurrence are the femur (42%),
the tibia (19%), and the humerus (10%) bones. OS usually initiates in the medullary
cavity of long bones and then spreads to the cortex. At the time of diagnosis, 80%
of the cases are localized in one bone and about 20% of newly diagnosed patients
present with the lung metastasis. Lung is the most common site of metastasis and
the main cause of mortality. Bone is known to be the second most common site
for metastasis while metastasis to other organs is very rare (2).
The current treatments for OS consists of neoadjuvant chemotherapy
followed by surgical resection of tumor and then adjuvant chemotherapy postoperatively. The advantage of neoadjuvant chemotherapy is tumor burden
reduction, and elimination of lung micrometastasis. The standard combinational
chemotherapy for OS include treatment with cisplatin, doxorubicin, high-dose
methotrexate with leukovorin rescue, and ifosfamide. Although there has been
remarkable improvement in the prognosis of patients with primary OS over the past
30 years, patients with local relapse or those that develop metastasis following
2

therapy experience significantly lower survival rates. Current treatments have
enhanced the 5-year survival rate of patients with non-metastatic OS to 70%;
however, for those who present with pulmonary metastasis, the 5-year survival
rate is less than 20% (3-5). New therapeutic modalities are needed to combat OS
especially for the disease at the metastatic stage which is resistant to standard
treatments such as chemotherapy and radiation.

Immunotherapy in osteosarcoma
Poor survival rates in patients with OS pulmonary metastasis highlights the
necessity

for

development

of

new

therapeutic

approaches,

including

immunotherapies. The immune system has a critical role in eliminating cancer,
thus any approach to up-regulate immunity against cancer may have a significant
impact on OS treatment (6). Current immunotherapy treatments available for
cancer can be classified into 6 broad categories:
1- Adoptive immunotherapy:
Adoptive immunotherapy refers to infusion of allogeneic or autologous
immune cells (T- or NK-cell) or antibodies in order to boost anticancer immune
response (7). Chimeric antigen receptor (CAR) T‑cells that have genetically
modified T cell receptors are considered as a promising cellular immunotherapy
for cancer. In brief patients T cells are removed and genetically modified with the
variable regions of antibodies specific to the targeted antigen on tumor cells and
re-introduced into the patient. Thus these specifically re-directed T cells will kill
antigen bearing tumor targets (8). Several clinical trials targeting sarcoma are
3

underway. Two phase I trials targeting the tumor antigen NY-ESO-1 on metastatic
and recurrent synovial sarcoma in children and adults (NCT01343043), or on
advanced NY-ESO-1-expressing sarcomas in patient receiving radiation
(NCT02319824) with CAR T-cells therapy are underway.
It has been shown that IL-11Rα is overexpressed on OS and in vivo studies
showed that IL-11Rα-CAR T cell therapy resulted in regression of OS pulmonary
metastasis (9). Human epidermal growth factor receptor 2 (HER2)-specific CAR T
cells resulted in tumor reduction in a mice model established with OS lung
metastasis (10). Adoptive immunotherapy using NK cells is considered as another
emerging immunotherapeutic modality for cancer which is a major focus of this
dissertation.
2. Therapeutic vaccines:
Therapeutic cancer vaccines trigger immune system to attack cancer cells
expressing tumor associated antigens. Vigil formerly known as FANG vaccine,
which expresses targeted antigen and GM-CSF, for patients with metastatic Ewing
sarcoma (NCT02511132) is in a phase II clinical trial; CMB305 vaccine is
developed for NY-ESO-1+ tumors for patients with advanced disease is in a phase
I trial (NCT02387125); DSP-7888 vaccine targeting WT1+ cancers including
sarcoma (NCT02498665), and dendritic cell vaccine for adults and children with
sarcoma (NCT01803152A) are in phase I trials.
3. Checkpoint inhibitors/immune modulators
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Checkpoint inhibitors are drugs or monoclonal antibodies used to block the
inhibitory receptor/ ligand to enhance the immune response otherwise they are
exhausted or energetic, e.g. blocking immune inhibitory molecules PD-1, PD-L1,
and CTLA4. Several antibodies blocking these molecules (check-point inhibitors)
are under evaluation in clinical trials (11).
Immunomodulation refers to taking advantage of immunomodulatory
agents such as cytokines to augment immunity against tumor cells nonspecifically
by activating innate immunity (mostly NK cells, monocytes, and macrophages). An
example of a promising immunomodulatory agent for OS treatment is Liposomeencapsulated Muramyl Tripeptide-Phosphatidyl Ethanolamine (L-MTP-PE). The
mechanism underlying the use of L‑MTP‑PE is that monocytes and macrophages
uptake the liposome-encapsulated MTP-PE and become activated and release
pro-inflammatory cytokines e.g. IL‑1β, IL-6, and tumor necrosis factor-α (TNF-α)
in the tumor microenvironment (12, 13). In relapsed OS patients, L-MTP-PE alone
or in combination with ifosfamide significantly increased the disease-free survival
rate (14). Adding L-MTP-PE to the standard chemotherapy resulted in a 29%
decreased mortality rate in newly diagnosed OS (15).
Interleukin-12 (IL-12), the key inducer of cell-mediated immunity, has also
been studied as an immuno-stimulatory agent for OS. Aerosolized delivery of
polyethylenimine (PEI) carrying the murine IL-12 gene (PEI: IL-12) to the lung of
mice with established OS lung micro metastasis demonstrated therapeutic
potential and dramatically reduced the number of lung metastases (16, 17).
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Aerosolized PEI: IL-12 also significantly increased the therapeutic effect of
ifosfamide for OS pulmonary metastases (18).
4. Oncolytic virus therapy
Oncolytic viruses selectively kill tumor cells by replicating inside the cell
whereas normal cells are resistant to this mechanism. A phase I/II trial of PexaVec (JX-594), a virus engineered to lyse cancer cells and induce GM-CSF-driven
tumor immunity, for patients with soft tissue sarcoma (NCT02630368) is ongoing.
5. Adjuvant immunotherapies
Adjuvants are substances that are used to boost immune response either
alone or in combination with other immunotherapies. Adjuvants can be either
stimulating or blocking antagonist ligands. For instance, Poly-ICLC (Hiltonol), a
Toll-like receptor 3 agonists is used as an adjuvant for several cancers including
sarcoma (NCT02423863)
6. Monoclonal antibodies
Monoclonal antibody-based treatment of immunotherapy for cancer has
been established as one of the most successful therapeutic strategies for both
blood malignancies and solid tumors for the past 20 years. Monoclonal antibodies
targeting

CD56-expressing

tumors,

including

synovial

sarcoma,

rhabdomyosarcoma (NCT02452554), GD2 antigen on neuroblastoma and
recurrent osteosarcoma (NCT02502786, NCT02484443), gpNMB antigen
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overexpressed by recurrent osteosarcoma (NCT02487979), RANK ligand, and in
children with osteosarcoma (NCT02470091) are in phase II clinical trials.

Natural killer cell biology and function
NK cells are a type of lymphocyte that play a major role in the innate immune
system against virus-infected and tumor cells (19). NK cell had initially been
identified in 1975 due to their killing activity against mouse leukemia cells (20). NK
cells develop from common lymphoid progenitor cells (CLPs) in bone marrow;
however, the precursors of NK cells are not fully characterized in humans.
Developed NK cells are distributed in lymphoid as well as non-lymphoid organs
i.e. BM, spleen, peripheral blood, lymph nodes and lung and liver (21). NK cells
represent 10– 15% of peripheral lymphocytes and are identified by the basic
immunophenotype as CD56+ CD3- cells.
In contrast to T cells, NK cells recognize their target cells without needing
antigen-specific receptors. Indeed, they become activated by the signals
transduced through a group of activating and inhibitory cell surface receptors. The
net balance between activating and inhibitory signals define the NK cell fate. When
the activating signals exceed the inhibitory signals, NK cells become activated
(22). Among activating receptors, natural killer group 2D (NKG2D) is the most wellcharacterized and effective receptor. NKG2D interacts with its ligands expressed
on target cells, including UL-16-binding proteins (ULBPs) 1–6 and the major
histocompatibility complex class I (MHC-I) polypeptide-related sequence (MIC) A
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and B and. Some other NK cell activating receptors include the natural cytotoxicity
receptors (NCRs) NKp30, NKp44, and NKp46 and DNAX accessory molecule-1
(DNAM-1). The respective ligands for NCRs are still unknown; however, it has
been shown that NK cells recognize their target cells at least in part through these
ligands. The ligands for DNAM-1, Nectin-2 (CD112) and poliovirus receptor (PVR,
CD155) are vastly expressed on several tumors, including sarcomas. Killer cell
immunoglobulin-like receptors (KIRs) and the CD94–NKG2A receptor are known
as NK cell inhibitory receptors that bind to the classic and non-classic human
leukocyte antigen (HLA) class I molecules (23-26).
NK cells kill tumor cells either by secreting cytotoxic granule or by inducing
apoptosis through its death-inducing receptors. To induce its cytotoxic function,
NK cell needs to contact its target cell through an immunological synapse in which
several receptors, signaling molecules and organelles are involved. This ensures
specific targeting of the cytolytic process to a single cell within a tissue without
adjacent cells being affected (27). Releasing cytotoxic granules (perforin and
granzymes) in the immunological synapse is considered as the most effective and
fastest way of NK cell killing function (28). NK cells may also induce apoptosis in
tumor cells by death-inducing Fas ligand (CD178), tumor-necrosis factor-related
apoptosis-inducing ligand (TRAIL), and TNF. These ligands bind to their receptors
(FAS and TRAIL receptor) on tumor cells and induce tumor-cell apoptosis (29). NK
cell also secrets various cytokines such as IFN-γ which promotes antiangiogenic
factors in tumors, increases NK cell cytotoxicity, and stimulates adaptive anticancer T cells (30).
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Natural killer cells and cancer immunotherapy
Adoptive transfer of activated NK cells in the autologous and allogeneic
setting has emerged as an effective immunotherapeutic strategy for cancer (31).
Although haploidentical hematopoietic stem cell transplant has been effective for
clinical benefit of NK cells, growing evidence suggests NK cell activity against
carcinomas and sarcomas (32).
Unlike T cells, NK cells have antigen-independent cytolytic activity against
tumor cells, thus allogenic NK cells can be infused with a decreased risk of graftversus-host disease (GVHD) in the recipient (33). Allogeneic ex vivo expanded NK
cells from healthy donors are also beneficial for cancer patients with nonfunctional
NK cells (34). Moreover, allogenic NK cell therapy can be even more effective
when there is a mismatch between KIR on donor NK cells and the KIR-ligand on
recipient tumor cells due to the absence of NK cell inhibitory signal (35). In fact,
enhanced NK cell tumor cytotoxicity owing to incompatibility between KIR and KIRligand was the original rational for the improvement of allogeneic NK cell therapy.
Allogenic NK cells can be transferred either in a hematopoietic cell transplantation
(HCT) setting or as an adoptive immunotherapy. NK cells can be purified and
expanded from healthy donor lymphapheresis products, umbilical cord blood, or
embryonic stem cells. Various methods for in vitro NK cell expansion have been
reported which use a combination of different cytokines and feeder cells. Our
method for NK cell expansion includes culturing of NK cells on irradiated K562 cell
expressing membrane-bound IL21 (mbIL21) supplemented with interleukin-2 (IL-
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2). This ethod results in rapid proliferation of NK cells with 21,000 fold expansion
in 21 days (36).
The first clinical trial of immune cell therapy was performed by Dr. Steven
Rosenberg and his group in 1980s by using lymphokine-activated killer (LAK) cells
and IL-2 in patient with metastatic melanoma (37, 38). Autologous PBMCs were
incubated with IL-2 to induce LAK cells. The feasibility and safety of allogenic NK
cell therapy was first shown by Miller and his colleagues in patients with poor
prognosis acute myeloid leukemia (AML). The haploidentical NK cells therapy
followed by subcutaneous IL-2 infusion daily for 2 weeks resulted in complete
remission in 5 patients out of 19 (31). Success in allogenic NK cell therapy in
patients with AML was the beginning of many clinical trials to investigate the safety
and efficacy of this cellular therapy for cancers, most of them in hematologic
malignancies (33, 39). However, it has been reported that adoptively transferred
allogeneic NK cells may have a therapeutic potential in solid tumors as well (40,
41).
Investigations suggest that NK cells are involved in OS prevention and
prognosis. A study of 44 children with OS showed that they had fewer numbers of
peripheral NK cells compare to the control group, supporting the role of NK cell in
preventing OS (42). OS patients who had early lymphocyte recovery after
chemotherapy

showed

a

better

prognosis

than

patients

with

late

lymphocyte recovery (43). Moreover, Buddingh and his collogues reported that
unlike patients with other types of cancer, NK cell function was normal in
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osteosarcoma patients and was able to lyse tumor cells, suggesting that NK cell
therapy may be beneficial for patients with OS (44).
Studies have shown that Osteosarcoma cells are sensitive to NK cellmediated cytotoxicity. For example Duck Cho et al., reported that human OS cell
lines are killed by activated NK cells (32). Furthermore, human OS primary cell
lines (either from primary OS or from lung metastasis) were susceptible to
activated NK cell killing due to the NKG2D-NKG2DL interaction (45). This study
also demonstrated that in a xenograft orthotopic OS model (NSG mouse) NK cell
therapy followed by IL-2 administration (10,000 IU IP injection/mouse) for 5 days,
resulted in significant primary tumor regression, no lung metastases, and an
increased survival rate. In our lab we also have shown that aerosol IL-2 combined
with NK cell therapy, significantly augments NK efficacy against OS lung
metastasis. Nude mouse model injected with human LM7cells i.v. which resulted
in the formation of metastasis in the lung. Although expanded human NK cell could
decrease the tumor burden in the lung, adding aerosolized IL-2 to the treatment
enhanced NK cell efficacy dramatically. Aerosolized IL-2 increased the number of
infused NK cells in the lung and in the metastatic tumor, but not in the other organs.
Moreover, NK cell therapy with aerosolized IL-2 improved the overall survival of
mice with established OS pulmonary metastasis (46, 47).
A phase I study of NK cell infusion after hematopoietic stem cell
transplantation in patients with solid tumors (including OS) is ongoing
(NCT01287104). Furthermore, infusion of activated NK cell line NK-92 in patients
with advanced OS has been completed; however, the results show that the
11

treatment was not clinically effective (48). Therefore, new approaches to augment
the efficacy of NK cell therapy for cancer treatment are necessary.

Histone deacetylase (HDAC) inhibitors
Epigenetic modifications such as DNA methylation and acetylation leads to
chromatin remodeling, altered gene expression and cellular phenotype. Genetic
defects in proteins regulating epigenetics results in loss or gain function and these
epigenetic aberrations leads to onset and progression of human disease (49).
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are
responsible for histone modifications. HAT stimulates gene transcription by adding
acetyl group to histones and unfolding the chromatin which in turn enables access
for transcriptional machinery to chromatin. While, HDAC remove the acetyl group
from histones and results in condense chromatin and less gene expression. In
human 18 HDACs have been identified and classified in four classes. Class I
includes HDAC 1, 2, 3, and 8; Class II includes HDAC 4, 5, 6, 7, 9, and 10; Class
III includes sirtuins; Class IV includes HDAC 11. Abnormal function of HDACs is
often associated with tumorigenesis and poor prognosis in cancer (50). Therefore,
HDACs have become promising therapeutic targets in cancer and other immune
related diseases (51). Several HDAC inhibitors having various target specificity
and pharmacokinetics have been synthesized (52) and many of them are in clinical
trials for treatment of malignancies. These inhibitors induce senescence,
apoptosis, growth arrest, and differentiation of cancer cells. Studies shows that
HDAC inhibitors are selectively cytotoxic to tumor cells while normal cells appear
12

to be resistant (53). Moreover HDAC inhibitors involve in chromatin remodeling by
allowing access for transcriptional machinery to chromatin resulting in controlled
gene expression, e.g. NK cell related genes NKG2D ligands, killer cell
immunoglobulin-like receptor, and 11 Ly49a (54, 55). HDAC inhibitors belong to
4 structural classes: benzamide, hydroxamic acid, cyclic peptides or short chain
fatty acid. Entinostat (MS-275) belongs to the benzamide group and known to be
a narrow-spectrum HDACi which affect HDAC class I with almost no effect on
HDAC 8. Entinostat is in clinical trial for treatment of both solid and hematological
malignancies (56).
Though HDAC inhibitors exhibited anticancer activity accumulating
evidence suggests that enhanced and efficient anti-tumor activity is achieved by
combination with other drugs or adaptive immunotherapy i.e NK cells. Studies
have shown that HDAC inhibitors play roles as immune modulators resulting in
enhanced recognition of tumor cells by immune cells (57). Cytotoxicity of natural
killer cells correlates with the interaction of their receptors (e.g NKG2D) with the
ligands (e.g., MICA and MICB) on target cells. Benzamide containing HDAC
inhibitor entinostat enhances NK cell- mediated cytotoxicity against cancer cells by
up-regulation of both NKG2D on NK cells and corresponding ligands on tumor (58).
Further, HDAC inhibitors, including entinostat, increased the susceptibility of
Ewing sarcoma cells for NKG2D-dependent cytotoxicity by NK cells (59).
Schmudde et.al showed that the HDAC inhibitors SAHA, sodium butyrate, and
entinostat treatment increased the susceptibility of prostate carcinoma and
medulloblastoma cell lines for NK killing using the same mechanism (60). These
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results are also in accordance with published data concluding that HDAC inhibitors
increase the susceptibility of tumor cells to NK cell-mediated cytotoxicity by
increasing the expression of MICA/B (61-63). The main focus of this thesis is
investigating the role of entinostat (MS-275) in enhancing NK cell-mediated killing
by upregulating NKG2D ligands on osteosarcoma tumor model as a combination
therapy.

MicroRNA biogenesis and function

MicroRNAs (miRNAs) are classified as a large family of small, non-coding,
and single-stranded RNAs. They consist of 21 to 25 nucleotides and negatively
regulate gene expression at the post transcriptional level. The biogenesis of a
miRNA happens by a series of processing events (64). The miRNA formation
starts with the genome transcription by RNA polymerase II which results in a long
Pri-miRNA precursor (pri-miRNA) generation.

Later, the nuclear Drosha5 –

DGCR86 complex (RNase III Drosha) cleaves pri-miRNA into a 60–70 nt miRNA
precursor (pre-miRNAs) which is then transported to the cytoplasm by the protein
exportin-5 (61, 65). In the cytoplasm the pre-miRNA will be processed to a mature
miRNA by RNase III Dicer (66, 67). The mature miRNA is then incorporated into
the RNA-inducing silencing complex (RISC) and binds to 3’ untranslated region
(3’-UTR) of the targeted mRNA which induces gene silencing by inhibiting of
mRNA translation or by promoting mRNA degradation (68).
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MiRNAs play an important role in the control of diverse biological processes
such as cell proliferation, differentiation, and death as well as the development and
differentiation of hematopoietic and immune cells (69). In cancer, expression of
specific miRNAs has been reported to be abnormal. Increasing evidence shows
that miRNAs play a crucial role in cancer initiation and progression, by controlling
tumor cell proliferation, differentiation, invasion, metastasis formation, and
apoptosis (70-72).
Stern-Ginossar and his colleagues introduced a group of miRNAs (miR520d, miR-373, miR-372, miR-106b, miR-93, and miR-20a) that suppress MICA
and MICB expression by targeting MICA and MICB mRNA 3’ UTR sites (73).
Knowing that many of these miRNAs are up-regulated in various tumors and play
a role in tumorigenesis (72, 74-76), they suggested that the overexpression of
relevant miRNAs provide a way for tumor cells to escape from immune cell
recognition. Overexpression of these miRNAs suppress MICA and MICB
expression in tumor cells and prevent them from being recognized by NK cells,
CD8+ T cells and γδ T cells that express NKG2D.
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Aim of the study
Our previous studies demonstrated that NK cell therapy has minimal
efficacy against OS metastasis. Considering the critical need for a new therapeutic
approaches for metastatic OS we aim to determine whether combining an HDAC
inhibitor entinostat with NK cells would augment the efficacy of NK cell therapy
against OS lung metastasis. Effect of entinostat on NK cell function investigated
both in vitro and in our nude mouse human OS lung metastasis model. We also
investigated the mechanism by which entinostat up-regulated NK cell ligands on
OS cells. We hypothesized that combining entinostat with NK cell therapy
would augment cytotoxic effect of NK cells against osteosarcoma lung
metastasis by increasing the ligands for activating NK cell receptors on OS
cells.
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RESULTS

Chapter 2
Entinostat up-regulates ligands for activating NK cell receptors on
osteosarcoma cells and makes them more susceptible to NK cell-mediated
cytotoxicity

17

RATIONAL
Our research group had previously shown that NK cell therapy in
combination with aerosol IL-2, significantly decreased tumor burden of human OS
lung metastasis in mice. However, this therapy failed to eliminate tumor completely
from the lungs (46, 47). It is well known that the level of NK cell-mediated
cytotoxicity against tumor cells is highly dependent on the number of NK cell
ligands on their surface and the interaction with the corresponding receptors on
NK cells. In order to increase the therapeutic efficacy of NK cell for OS pulmonary
metastasis, we decided to enhance NK cell ligand expression on OS cells and for
that purpose we investigated combining the HDAC inhibitor entinostat with NK cell
therapy. We hypothesized that entinostat would sensitize tumor cells to the
cytotoxic effects of NK cells, by increasing cell surface ligand expression specific
to the NK cell activating receptors. A similar effect of HDAC inhibitors has been
reported in other studies. For example, Schmudde et.al, showed that HDAC
inhibitors SAHA, sodium butyrate, and entinostat treatment increased the
susceptibility of prostate carcinoma and medulloblastoma cell lines for NK killing
using the same mechanism (60). Ewing sarcoma cells treated with HDAC inhibitors
including entinostat had enhanced susceptibility NKG2D-dependent cytotoxicity by
NK cells (59).
To determine whether entinostat would increase NK cell ligands on OS
tumor cells in vitro, we treated OS cell lines with entinostat and evaluated surface
ligand expression by flow cytometry. We also assessed mRNA and protein levels
of NK cell ligands by quantitative real-time PCR and western blot respectively. To
18

examine whether entinostat enhances OS cell sensitivity to NK cell mediated
cytotoxicity, we used the calcein release assay. Using blocking antibodies against
NK cell receptors, we showed that NK cell-mediated cytotoxicity against OS cell is
dependent on receptor and ligand interaction.

RESULTS
Entinostat up-regulates ligands for activating NK cell receptors on OS cells
To determine whether entinostat would increase the expression of ligands
specific for activating NK cell receptors on OS cells, various human OS cell lines
(LM7, CCH-OS-D, CCH-OS-O, and KRIB) were treated with 2 µM entinostat (≤
IC50) for 48 hours and analyzed by flow cytometry. Entinostat treatment
significantly up-regulated ligands for NK cell–activating receptors but did not affect
the ligand for the NK cell inhibitory KIR receptor (HLA-ABC). The up-regulated
ligands included CD155 (except for CCH-OS-D and KRIB), MIC A/B, ULBP1, and
ULBP2/5/6 (figure 1).
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Figure 1. The effect of entinostat on the expression of NK cell ligands on
OS cells. Human OS cells LM7 (A), CCHOSD (B), CCHOSO (C), and KRIB cell
(D), were incubated with 2 μM entinostat for 48 hours and NK ligand expression
analyzed by flow cytometry. The level of receptor ligand expression is indicated
as a mean fluorescence intensity (MFI). P value < 0.05 are marked with *. All
experiments were repeated three times, bars show mean +/- S.E.M.

MICA and MICB are major ligands of NKG2D, and the NKG2D–MICA/B
interaction plays a major role in NK cell activation. Therefore, we investigated the
effect of entinostat on MICA/B mRNA and protein expression as well. LM7 cells
were incubated with 0, 0.5, 1.0, or 2 μM entinostat for 48 hours and total RNA was
extracted using Trizol reagent and analyzed by quantitative real-time PCR (qRTPCR) using primers specific for MICA and MICB. Protein levels of MICA/B from
whole cell lysate were analyzed by western blot. LM7 cells treated with entinostat
showed increased mRNA (figure 2A) and protein expression (Figure 2B) levels for
MICA and MICB in a dose dependent manner.

A
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B

Figure 2. The effect of entinostat on MICA and MICB mRNA and protein
expression in LM7 cells. (A) LM7 cells were incubated with 0, 0.5, 1.0, or 2 μM
entinostat for 48 hours. RNA was extracted and MICA and MICB mRNAs were
measured by quantitative real-time PCR using specific primers for MICA and
MICB. (B) MICA and MICB protein levels determined by western blot from LM7
whole cell lysate treated with increasing doses of entinostat 0.5, 1.0, or 2 μM.
Untreated cells used as control. Bars show mean +/- S.E.M, n=3.

Next, we determined the stable expression of the increased ligands for NK
cell receptors on OS cells in response to entinostat treatment. LM7 and CCH-OSD cells were incubated with 2 μM entinostat, and fresh medium was added after
48 hours. Cells were harvested at the end of 48 h of treatment, at 24, 48, and 72
h after replacing the media. Cells were examined for MICA/B, ULBP1, and
ULBP2/5/6 expression by flow cytometry. As mentioned before, treatment with 2
µM entinostat for 48 hours significantly increased MICA/B, ULBP1, and ULBP2/5/6
expression on OS cells (figure 1). The findings from this experiment demonstrated
that the expression of up-regulated ligands on OS cells were stable for more than
24 h after the drug was removed from the culture media, suggesting that for the in
vivo study there can be a window of time between drug administration and the
initiation of NK cell therapy since the up-regulated ligands are stable for at least 24
h.
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Untreated
2 uM
entinostat for
48 h
24 h after
drug
withdrawal
48 h after
drug
withdrawal
72 h after
drug
withdrawal

ULBP1
MFI
CCHOSD
LM7
16.3
7.9

ULBP2/5/6
MFI
CCHOSD LM7
43.0
77.0

MIC A/B
MFI
CCHOSD
LM7
36.9
151.0

29.6

29

85.8

156

61.5

335

30.7

24

86.0

150

72.6

306

26.7

16

77.7

86

67.4

273

27.1

11.2

74.3

67

70.3

270

Table 1. Up-regulated NK cell ligands on OS cells by entinostat are stable
for more than 24 h. LM7 and CCH-OS-D cells were treated with 2 µM entinostat
for 48 hours followed by replacing the conditioned media with fresh media. Cells
were harvested at the end of 48 hours treatment and 24, 48, and 72 h after
replacing the media and analyzed by flow cytometry with antibodies specific for
MICA/B, ULBP1, and ULBP2/5/6.

Entinostat increases OS cell susceptibility to NK cell-mediated cytotoxicity

Having shown the stable expression of ligands for NK cell receptors on OS
cells in response to entinostat treatment, we next hypothesized that the increased
expression of ligands on OS cells would enhance NK-cell mediated cytotoxicity.
The underlying rationale was that increased expression of NK cell ligands on tumor
cells would make them more susceptible to NK cell-mediated cytotoxicity. To prove
our hypothesis, control and entinostat-treated LM7 cells were incubated with 1 µM
calcein-AM at 37οC for 1 hour and then were co-cultured with ex vivo activated NK
cells in various effector-to-target cell ratios (0.3, 0.6, and 1.3) for 4 hours. The
24

amount of lysis was quantified using a fluorescence plate reader at excitation and
emission wavelengths of 485 nm and 530 nm, respectively. Our findings revealed
that OS cells treated with entinostat were more sensitive to NK cells and were
killed more effectively than control cells (Figure 3A and 3B).

A

B
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Figure 3. The effect of entinostat on OS cell susceptibility to NK cellmediated cytotoxicity. Entinostat treated and control OS cells (A) LM7 (B)
CCHOSD were labeled with 1 µM calcein-AM at 37οC for an hour and washed
with RPMI media and co-cultured with ex vivo expanded NK cells at effector to
target cell (E:T) ratio of 0.3, 0.6, and 1.3 for 4 hours. P value < 0.05. Data pooled
from three independent experiments. Bars show mean +/- S.E.M.

To demonstrate that NK cells recognize and kill OS cells via NK cell receptor
and ligand interaction, we blocked NK cell receptors with the use of blocking
antibodies specific to NKG2D, NKp46, and DNAM receptors and then co-cultured
them with untreated LM7 or 2 µM entinostat treated LM7 cells for 48 hours. NK
cells not treated with blocking antibodies were used as control. Our data indicated
that blocking NK receptors abolished NK cell cytotoxic activity against both
untreated and treated OS cells (Figure 4A and 4B, respectively), confirming that
NK cell-mediated cytotoxicity for OS cells is dependent on receptor and ligand
interactions.
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Figure 4. NK cell-mediated cytotoxicity against OS cells is dependent on
receptor and ligand interaction. Untreated LM7 cells or pretreated LM7 cells with
2 µM entinostat for 48 hours (Fig 4A and 4B, respectively) were used in calcein
release assay. LM7 cells were labeled with 1 µM calcein-AM at 37οC for 1 hour
and co-cultured with ex vivo expanded NK cells pre-treated with blocking
antibodies specific to NK cell receptors for 4 hours at 37 οC. NK cells not treated
with blocking antibodies were used as control. Bars show mean +/- S.E.M, n=3.
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SUMMARY
These data support our hypothesis that entinostat enhances the expression
of ligands for activating NK receptors on OS cells and sensitizes them for NK cellmediated cytotoxicity. Entinostat increased MICA/B, ULBP1, and ULBP2/5/6 on
four human OS cell lines (LM7, CCH-OS-D, CCH-OS-O, and KRIB), making them
more susceptible to NK cell mediated killing. The increased ligands are stable for
more than 24 hours after drug removal from the culture media. By blocking NK cell
receptors, we also demonstrated that NK cells recognized and lysed OS cells
through interaction between NK cell receptors and their corresponding ligands on
the OS cells.
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RESULTS

Chapter 3
Entinostat does not affect NK cell viability, receptor expression, or
cytotoxic function
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RATIONALE
Since the final goal of this study was to use combination therapy with NK
cells along with entinostat for the treatment of OS lung metastasis in a mouse
model, we needed to determine whether the drug had any adverse effects on NK
cell viability, receptor expression, and cytotoxic function to ensure that NK cell
therapeutic efficacy in clearing tumors is not compromised. It has been reported
that HDAC inhibitors including suberoylanilide hydroxamic acid (SAHA) and
valproic acid reduced NK cell cytotoxic function against leukemic cells due to their
inhibitory effects on NK cell activating receptor expression (77). However, based
on another study, entinostat increased NK cell-mediated cytotoxicity against
sarcomas by up-regulating both NK cell activating receptors and their ligands on
tumor cells (58). To evaluate the effect of entinostat on NK cells, we treated ex
vivo expanded and activated NK cells with various doses of the drug for 24 and 48
hours and then examined the NK cell viability, receptor expression and cytotoxic
function.

RESULTS
Entinostat has no effect on NK cell viability
To determine whether entinostat has any effect on the viability, NK cells
were expanded ex vivo for 4 weeks and treated with 0, 0.1, 0.5, 1.0, and 2.0 µM
entinostat. Cells were collected after 24 and 48 hours and their viability was
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assessed using Vi-CELL. Our data indicated that neither 24 nor 48-hour treatment
with various doses of entinostat affected NK cell viability (figure 5).

24 h
Treatment

Figure 5. Entinostat does not affect NK cell viability. Ex vivo expanded NK
cells were incubated with various concentrations of entinostat 0, 0.1, 0.5, 1.0, and
2 µM. Cells were harvested after 24 and 48 hours and NK cell viability was
assessed by using Vi-CELL. Untreated NK cells were used as control. Data was
shown as mean +/- S.E.M, n=3.
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NK cell receptor expression is not affected by 24 hour treatment with
entinostat
To determine whether entinostat had any negative affect on NK cell receptor
expression, ex vivo expanded NK cells were treated with 0, 0.1, 0.5, 1.0, and 2.0
µM entinostat for 24 and 48 hours. NK cell receptors NKG2D, NKp30, NKp44,
NKp46, and DNAM-1 expression was analyzed by flow cytometry. Though dose
dependent entinostat treatment for 24 hours did not change NK cell receptor
expression, after 48 hours higher doses of the drug decreased NK cell receptors
expression, except for the DNAM-1 (figure 6). These findings suggests that
entinostat concentration of ≥ 0.5 µM for 48 hours may down-regulate the
expression of NK cell activating receptors. Thus, for the in vivo study, care has to
be taken not to administer the drug and NK cells on the same day, but with at least
24 hours duration between drug and NK cell administration to avoid adverse
effects on NK cell receptor expression.
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Figure 6.Treatment with entinostat for 24 hours does not affect NK cell
receptor expression. Ex vivo expanded NK cells were treated with 0, 0.1, 0.5,
1.0, and 2.0 µM entinostat for 24 and 48 hours. Cells were stained with antibodies
specific to NKG2D, NKp30, NKp44, NKp46, and DMAM-1. NK cell receptors
expressions were analyzed by flow cytometry. The expression levels were shown
as a mean fluorescence intensity (MFI). P value < 0.05 are marked with *. Bars
show mean +/- S.E.M, n=3.

Entinostat treatment does not affect the NK cell-mediated cytotoxicity
against OS cells
Having shown that entinostat treatment did not alter NK cell receptor
expression within 24 hours of treatment, we also sought to determine whether
entinostat had any negative effect on NK cell cytotoxic function. OS cells were
incubated with 1 µM calcein-AM at 37οC for 1 h. Cells were washed with RPMI
media and co-cultured with control or entinostat-pretreated NK cells (2 µM for 24
h) at the effector: target cell ratio of 0, 0.3,0.6,1.3, 2.5,5,10. Plates then were
incubated at 37οC for 4 h. Following incubation, 100 μL of the supernatant was
harvested and transferred to a new plate and absorbance was assessed using a
spectrophotometer. Our results indicated that NK cells pre-treated with entinostat
had almost the same level of cytotoxicity against both LM7 and CCH-OS-D cells
compared to the cytotoxicity of untreated NK cells (figure 7), suggesting that
entinostat does not abrogate NK cell functional activity within 24 hours of
treatment.
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Figure 7. Entinostat does not reduce NK cell-mediated cytotoxicity against
OS cells within 24 h treatment. OS cells were incubated with 1 µM calcein-AM
at 37οC for 1 hour. Cells were washed with RPMI media and co-cultured with
pretreated NK cells with entinostat (2 µM for 24 h) at a ratio of 0, 0.3,0.6,1.3,
2.5,5,10 (effector cell: target cell). Untreated NK cells served as control. Plates
then were incubated at 37οC for 4 h. A total of 100 µL of supernatant was
transferred a new plate. The plate was read at excitation and emission
wavelengths of 485 nm and 530 nm, respectively. Bars show mean +/- S.E.M, n=3.
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SUMMARY

Our data support that 48 h treatment with up to 2 µM entinostat is not
cytotoxic for ex vivo activated NK cells and does not reduce NK cell viability.
Furthermore, the drug does not decrease NK cell activating receptor expression
within the 24 h of treatment; however, our finding showed that 48 h treatment
with ≥ 0.5 µM may affect the NK cell receptor expression. These data suggest
that for in vivo studies it is optimal to administer the treatments on different days
to avoid any possible adverse effect of the drug on NK cell function. As we have
shown, there is stable expression of the up-regulated NK cell ligands on OS cells
in response to entinostat treatment (Table 1). But the NK cell receptor expression
is decreased with > 24 h entinostat treatment. Then we decided to have 24 hours
in between the entinostat treatment and infusion of NK cells to avoid any adverse
effect on NK cell cytotoxicity. Finally, we have shown that 24 h pretreatment with
entinostat does not affect the NK cell-mediated cytotoxicity against OS cells
(Figure 7).
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RESULTS

Chapter 4
Entinostat controls MICA/B expression in OS cells by increasing
acetylation of histone 4 linked to the MICA and MICB gene promoters.
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RATIONALE
We demonstrated previously that entinostat increased the expression of
ligands for activating NK cell receptors on OS cells (MIC A/B, ULBP1, and
ULBP2/5/6). Next we wished to investigate the underlying mechanism by which
entinostat enhances expression of these ligands on OS cells. We decided to focus
on MICA and MICB, known to be the most important ligands for NKG2D. As an
HDAC inhibitor, entinostat stimulates gene transcription by adding acetyl group to
histone and unfolding the chromatin which in turn enables access for
transcriptional machinery to chromatin (51). We hypothesized that histone
acetylation by entinostat at MICA and MICB gene promoters leads to increase in
MICA and MICB gene expression in OS cells. A previous study showed that
increased acetylation of histones3 (AcH3) binds to the promoters of MICA and
MICB is correlated with enhanced MICA and MICB expression in a colon
carcinoma cell line treated with entinostat (58). The histone deacetylase inhibitor
SAHA has also been shown to enhance MICA/B gene transcription by promoting
MICA-associated histone acetylation (78).
To examine our hypothesis we first investigated whether entinostat
increases total acetylated H3 and H4 in LM7 cells by using western blotting.
Thereafter, chromatin immunoprecipitation (CHIP) assay was performed to
compare the level of acetylated histone 3 and histone 4 in untreated and treated
LM7 cells (2 µM entinostat for 48 hours).
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RESULTS
Entinostat increases acetylated H3 and acetylated H4 in OS cells in a dose
dependent manner.
We first determined whether acetylation of Histone 3 and 4 is increased in
LM7 cells treated with entinostat. Lysates of control and LM7 cells pretreated with
0.5, 1.0, or 2.0 µM entinostat for 48 hours was prepared and acetylated H3 and H4
protein levels were analyzed by western blotting. Our results showed that
entinostat enhanced acetylated H3 and acetylated H4 expression in a dose
dependent manner compared to untreated control cells (Figure 8).
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Figure 8. Entinostat increases acetylated H3 and acetylated H4 in LM7 in a
dose dependent manner. LM7 cells were treated with 0, 0.5, 1.0, or 2.0 µM
entinostat for 48 h. Cells were harvested and proteins were extracted. Western
blotting was performed using rabbit anti-human acetyl-histone3 or rabbit antihuman acetyl-histone4 antibodies to detect total acetylated H3 and acetylated H4
levels, respectively.

Acetylation of histone 4 linked to the MICA and MICB gene promoters
contributes to up-regulation of MICA/B expression by entinostat.
We performed the CHIP assay to confirm that one of the mechanism by
which entinostat up-regulates MICA and MICB gene expressions in OS cell is by
enhancing MICA- and MICB-associated histone acetylation. LM7 cells were
treated with 2 µM entinostat for 48 hours and cell lysates were treated with 1%
formaldehyde to crosslink protein and DNA. Lysates were sonicated to shear
chromatin to 200-1000 bp in length. Then, chromatins were immunoprecipitated
by using the following antibodies: anti-acetyl-histone H3, anti-acetyl-histone H4,
anti-histone H3, anti-histone H4, or control IgG. MICA and MICB promoter regions
were amplified by using quantitative real-time PCR. Two different sets of primers
for MICA or MICB promoters and two different antibodies specific for acetylated
H3 were used to confirm the accuracy of the results. After normalizing the readings
to inputs, the results were presented as a ratio of acetylated histone (H3 or H4) to
total histone (H3 or H4). The data suggested that entinostat significantly increased
acetylated H4 linked to the MICA and MICB promoters, but did not have any
significant effect on acetylation of H3 (Figure 9). Together, these data suggest that
increased acetylation of H4 associated with MICA and MICB gene promoters may
play a role in enhancing MICA and MICB expression induced by entinostat.
40

Figure 9. H4 acetylation associated with MICA and MICB gene promoters
contributes to up-regulation of MICA/B expression by entinostat in OS cells.
LM7 cells were treated with 2 µM entinostat for 48 h. Chromatins were
immunoprecipitated using the following antibodies: anti-acetyl-histone H4, antiacetyl-histone H3, anti-histone H4, anti-histone H3, or control IgG. MICA and
MICB promoter region were amplified by using quantitative real-time PCR. Two
different set of primers for MICA or MICB promoters and two different antibodies
against acetylated H3 were used to confirm the accuracy of the results. Bars show
mean +/- S.E.M, n=3.
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SUMMARY

We have shown previously that entinostat increases ligands for NK cell
receptors on OS cells (figure 1). In this chapter we aimed to explore the underlying
mechanism of how entinostat upregulates NK cell ligands on OS cells with the
main focus on NKG2D ligands MICA and MICB. We investigated whether upregulation of MIC A/B expression by entinostat is associated with increased
histone acetylation of MICA/B gene promoters, using CHIP assay. Our findings
showed that entinostat increased acetylated H3 and acetylated H4 in LM7 in a
dose dependent manner. CHIP assay revealed that entinostat enhanced the
accumulation of acetylated histone 4, but not acetylated histone 3 on chromatin
linked to both MICA and MICB genes.
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RESULTS

Chapter 5
Entinostat controls MICA and MICB expression in osteosarcoma tumor
cells by down-regulating miR-20a, miR-93, and miR-106b expression.
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RATIONALE
Stern-Ginossar et. al., reported that cellular miRNAs including miR-520d,
miR-373, miR-372, miR-106b, miR-93, and miR-20a control MICA and MICB
expression by targeting their mRNA 3’ UTR sites (73). They demonstrated that
miR-20a, miR-93, miR-106b were ubiquitously expressed in all the cell lines that
they examined (including: 293T, JEG3, DU145, RKO, HFF, and Me1-A1 cells);
however, miR-372, miR-373, and miR-520d expression was dependent on cell
type. Consistent with their results our findings also confirmed no expression of
miR-372, miR-373, and miR-520d in OS cells. Therefore, we chose to study the
role of miR-20a, miR-93, and miR-106b in MICA and MICB expression in OS cells.
miRNAs can inhibit gene expression by binding to the 3’UTR of the targeted
mRNA resulting in either inhibition of mRNA translation or its degradation. In this
chapter we also sought to understand the mechanism by which miR-20a, miR-93,
and miR-106b down-regulate MICA and MIC/B expression in OS cells.
We have shown in chapter 4, figure 9 that increasing the acetylation of
histone 4 on chromatin linked to the MICA and MICB gene promoters might be one
of the mechanism that entinostat uses to up-regulate MICA and MICB expression
on OS cell surface. In this chapter we further demonstrate another molecular
mechanism by which entinostat can increase MICA and MICB expression, i.e.
through down-regulation of miR-20a, miR-93, and miR-106b expression. Similarly,
a study done by H Yang et.al, indicated that the histone deacetylase inhibitor
SAHA also up-regulated MICA expression in hepatocellular carcinoma cells (HCC)
by suppressing miR-20a, miR-93 and miR-106b expression (78).
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RSULTS
MiR-20a, miR-93, and miR-106b regulate MICA and MICB expression in OS
cells.
The role of miR-20a, miR-93, and miR-106b in regulating MICA and MICB
expression was examined in OS cell lines. LM7 and KRIB cells were transiently
transfected with the miR-20a, miR-93, and miR-106b mimics or control miRNA.
These cell lines were chosen for the study because of high levels of MICA and
MICB expression on the surface. Overexpression of miRNA in transfected cell lines
was confirmed by quantitative RT-PCR (figure10A and 10B).
Cells were harvested 24 and 48 hours after transfection and MICA and MICB
expression levels were analyzed by flow cytometry. Consistent with the studies
done by Stern-Ginossar et al., our data showed that these miRNAs down-regulated
MICA and MICB expression in LM7 and KRIB cells 24 and 48 hours post
transfection (figure 10C and 10D). These results supported the role of miRNAs i.e
miR-20a, miR-93, and miR-106b in regulating MICA and MICB expression in OS
cells.
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Figure 10. miR-20a, miR-93, and miR-106b down-regulate MICA/B expression
in OS cells. miR-20a, miR-93, or miR-106b mimics or control miRNA were
transiently transfected into LM7 and KRIB cell lines that express high levels of
MICA/B. (A) Overexpression of miRNA in LM7 cells was confirmed by quantitative
RT-PCR after 24 and 48 hours (B) Overexpression of miRNA in KRIB cell line was
confirmed by quantitative RT-PCR 6 and 12 hours post-transfection. (C) LM7 and
(D) KRIB cell lines were analyzed for MICA and MICB expression by flow cytometry
24 and 48 hours after miRNA transfection. Red lines: cell transfected with miRNA
mimics; gray lines: cells transfected with control miRNA. Bars show mean +/S.E.M, n=3.

Down-regulation of MICA and MICB expression by miR-20a, miR-93, and
miR-106b is not controlled by MICA and MICB mRNA degradation.
mirRNAs can induce gene silencing by either inhibition of mRNA translation
or by promoting mRNA degradation and both mechanisms result in reduced
protein expression level. We over-expressed miR-20a, miR-93, or miR-106b in
LM7 cells and measured MICA and MICB mRNA levels. Our results showed no
significant changes in MICA and MICB mRNA levels in LM7 transfected with miR20a, miR-93, or miR-106b (figure 11B-11D). These findings suggest that MICA and
MICB down-regulation in LM7 by miRNAs may be secondary to the inhibition of
mRNA translation rather than the degradation of the mRNA.
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Figure 11. miR-20a, miR-93, and miR-106b decreases MICA and MICB
expression in OS cell lines but has no effect on total mRNA levels. (A) miR20a, miR-93, or miR-106b mimics (orange lines) or control miRNA (blue lines) were
transiently transfected into LM7.Cells were collected 48 h following transfection
and were analyzed by flow cytometry for MICA/B expression. (B-D) Total RNA was
extracted 24, 36, and 48 h following miRNA transfection and MICA and MICB
mRNA levels were measured by using quantitative RT-PCR. Bars show mean +/S.E.M, n=3.

Entinostat up-regulates MICA and MICB expression by down-regulating miR20a, miR-93, and miR-106b in OS cells in vitro and in vivo.
Having shown previously that entinostat significantly increased the
expression of MICA/B (chapter 2, figure 1) and that miR-20a, miR-93, and miR106b down-regulated MICA/B expression in OS cell lines (chapter 5, figure 10C
and 10D), next, we hypothesized that entinostat indirectly controls MICA/B
expression by down-regulating miR-20a, miR-93, and miR-106b in OS cells. To
test this hypothesis, three OS cell lines LM7, CCH-OS-D, and CCH-OS-O were
treated with 2 µM entinostat for 48 hours. Quantitative RT-PCR analysis revealed
that all three miRNAs were significantly decreased in the entinostat treated OS cell
lines compared to the control samples (figure 12A). We also sought to investigate
whether entinostat regulates MICA and MICB expression in OS lung metastasis
by reducing miR-20a, miR-93, and miR-106b using in vivo mouse model.
Approximately 2 × 106 LM7 cells, a human OS cell line that forms direct metastasis
in the lung, were injected intravenously into nude mice. After visible nodule
formation in the lung, the mice were treated with 5 mg/kg entinostat by oral/gavage
three times a week for 2 weeks. Control mice were treated with DMSO. The mice
were the euthanized, total RNAs were extracted from lung nodules, and MICA and
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MICB mRNA levels as well as miRNA expression were evaluated by quantitative
RT-PCR. Results indicated that 5 mg/kg entinostat significantly increased MICA
and MICB mRNA levels (figure 12B) and decreased miR-20a, miR-93, and miR106b in OS lung metastasis (figure 12C). These in vitro and in vivo results indicate
that entinostat treatment regulates MICA and MICB expression by down-regulating
miR-20a, miR-93, and miR-106b expression in OS cells and also in lung
metastasis.

A
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Figure 12. Entinostat regulates MICA and MICB expression by downregulating miR-20a, miR-93, and miR-106b expression. (A) LM7, CCH-OS-D,
and CCH-OS-O cell lines were treated with 2 µM entinostat for 48 h. Total RNAs
were isolated with the use of Trizol reagent. Reverse Transcription was performed
using TagMan miRNA reverse transcription kit. The resulting cDNA was subjected
to PCR amplification using primers specific for mir-20a, mir-93, or mir106b. (B, C)
Mice were injected with 2× 106 LM7 cells intravenously. Following visible nodule
formation in the lung, mice were treated with 5mg/kg entinostat three times a week
for two weeks. Control mice received DMSO instead. Thereafter, mRNA was
extracted from lung nodules and (B) MICA and MICB mRNA levels and (C) miRNA
expression were evaluated by quantitative RT-PCR. Data shown mean + S.E.M.
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SUMMARY
In this chapter we demonstrated that expression of MICA and MICB is regulated
by miR-20a, miR-93, and miR-106b in OS cells lines. We also showed that miR20a, miR-93, and miR-106b down-regulate MICA and MICB expression without
altering the mRNA levels, suggesting that the effect is through the inhibition of
MICA and MICB mRNA translation. Our data support the conclusion that entinostat
increases MICA and MICB expression by down-regulating miR-20a, miR-93, and
miR-106b.
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RESULTS

Chapter 6
NK cell therapy in combination with oral administration of entinostat in
mice with OS pulmonary metastasis
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RATIONALE
In the previous chapters we showed that entinostat up-regulates MICA/B
expression in OS cells in vitro (figure 1) and in OS lung metastasis in vivo (figure
12B), and also enhances ULBP2/5/6, and CD155 in OS cell lines in vitro (figure 1).
Increased expression of NK cell ligands on OS cells should enhance NK cellmediated cytotoxicity as we showed in our in vitro experiments. Accordingly, we
hypothesized that combination therapy using entinostat with NK cells would
enhance NK cell therapeutic effect in our mouse model with established OS lung
metastasis.

It

has

been

reported

previously

in

a

mouse

model

(NOD.CgRag1tm1MomPrf1tm1Sdz/SzJ) with fibrosarcoma lung metastasis, that
treatment with NK cells and entinostat significantly lowered tumor burden. (58).
Further, in a xenograft orthotopic OS model (NSG mouse), mice treated with NK
cells and IL-2 (10,000 IU IP injection/mouse) had reduced bone damage, lower
tumor burden in the tibia, and longer survival rates with no lung metastasis when
compared to control group (45).

RSULTS
Five mg/kg is the lowest dose of entinostat that significantly increases MICA
and MICB mRNAs in OS lung metastasis.
Before initiating our in vivo study with combination NK cells and entinostat
therapy, we first wished to determine a sub-therapeutic dose of entinostat that can
significantly increase the expression of NK cell ligands on the OS lung metastasis.
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Approximately, 2 × 106 LM7 cells were injected via tail vein into nude mice. After
visible nodule formation in the lungs, the mice were treated with entinostat of 2.5,
5, or 10 mg/kg by oral/gavage three times a week for 2 weeks (figure 13). Our
group had previously demonstrated that 20 mg/kg of entinostat has a therapeutic
effect against OS lung metastasis and inhibits tumor growth (79). Therefore, the
highest dose of the drug we examined was 10 mg/kg. At the end of the treatment,
total RNA was extracted from the lung tumors and MICA and MICB mRNA levels
were evaluated by using quantitative RT-PCR. The results demonstrated that both
5 and 10 mg/kg entinostat significantly enhanced the MICA and MICB mRNA
levels; however, 2.5 mg/kg of entinostat did not significantly increase the MICA
and MICB mRNAs (figure 14). Thus, we chose to use 5 mg/kg entinostat in our
animal study as the lowest dose that significantly increased MICA and MICB
ligands in OS lung metastasis.
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Figure 13. Schematic of mice experimental design to determine subtherapeutic dose of entinostat for increasing MICA and MICB mRNA levels.
Approximately 2× 106 LM7 cells in 0.2 mL of PBS were injected into nude mice
through the tail vein. Following visible nodule formation in the lung, mice were
treated with 2.5, 5, 10 mg/kg entinostat by oral/gavage 3 times a week for 2 weeks.
Mice were sacrificed and total RNA was extracted from lung nodules. MICA and
MICB mRNA levels were determined by quantitative RT-PCR.

Figure 14. Determining the lowest dose of entinostat that significantly
increases MICA and MICB mRNAs in OS lung metastasis. 2× 106 LM7 cells
suspended in 0.2 mL of PBS was injected into nude mice. Following visible nodule
formation in the lungs, mice were treated with entinostat concentrations of 2.5, 5,
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or 10 mg/kg by oral/gavage 3 times a week for 2 weeks. At the end of the treatment
nodules were removed from the lungs and total RNA was extracted and MICA and
MICB mRNA levels were determined by quantitative RT-PCR. Data was shown as
mean + S.E.M, n=5.

NK cells used for immunotherapy were highly activated and functional.
Human NK cells were isolated from normal donors’ buffy coats and were
expanded in vitro for 4 weeks using genetically engineered K562 supplemented
with 50 IU/ml recombinant human IL-2. K562 cells were used as an artificial
antigen-presenting cell (aAPC) to propagate NK cells in vitro. The genetically
engineered K562 expressed IL-21, CD86 (B7-2), CD64 (FccRI), and CD137L (41BBL).
Expanded NK cells were depleted for CD3+ T cells and had basic
phenotype CD3- CD56+ (Fig 15A). Their receptor expression i.e. NKG2D, CD16
and functional activity were also evaluated before being used in vivo. All expanded
NK cells were ≥ 95% and ≥ 80% positive for NKG2D and CD16, respectively. The
expanded NK cells were also tested for their cytotoxicity against LM7 cells before
Infusing into mice. At a ratio of 0.3:1 and 10: 1 (effector: target cell ratio), NK cellmediated cytotoxicity against LM7 cell were 22± 5 and 93± 3 respectively (figure
15B). Our data demonstrated that NK cells from all donors were healthy and
functional after four weeks of being expanded in vitro.
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Figure 15. Ex vivo expanded NK cells were fully activated and highly
functional. Human NK cells were purified from blood buffy coats and were
expanded in vitro for 4 weeks using genetically engineered K562 and recombinant
human IL-2. (A) NKG2D and CD16 receptor expression on NK cells after 4 weeks
of expansion assessed by flow cytometry. (B) Representative in vitro cytotoxicity
of expanded NK cells for OS cell LM7 by calcein release assay. Target cells
labeled with 1 µM calcein-AM and incubated at 37οC for 1 h. Cells were washed
with RPMI media and co-cultured with ex vivo expanded NK cells in 96-well Ubottom plates at a ratio of 0.3, 0.6, 1.3, 2.5, 5, and 10 (effector: target cell ratio).
Plates were incubated at 37οC for 4 h. 100 µL of supernatant was transferred to a
96-well flat bottom plate. The plate was read at excitation and emission
wavelengths of 485 nm and 530 nm, respectively.
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NK Cell therapy in combination with entinostat treatment did not inhibit
tumor growth in mice with osteosarcoma lung metastases.
We demonstrated that entinostat sensitized OS cells to NK cell-mediated
cytotoxicity by up-regulating the ligands for NK cell activating receptors, in vitro;
therefore, we anticipated that adding entinostat to NK cell therapy would increase
the therapeutic effect of NK cells for OS lung metastasis. To test this, we used our
established OS pulmonary metastasis mouse model in which nude mice were
injected with 2 × 106 LM7 cells via the tail vein. Pulmonary micrometastasis
formation in 3 mice euthanized at week 5 was confirmed by H&E staining of
paraffin-embedded lung section. After confirmation of micrometastsis formation,
treatment was initiated in four groups of mice with DMSO, entotstat, NK cells+
DMSO, or entinostat+ NK cells for five weeks. A total of 12-16 mice were included
in each group (figure 16).
We previously demostrated that up-regulated ligands on OS cells (MIC A/B,
ULBP1, and ULBP2/5/6) by entinostat are stable for more than 24 h (Table 1),
suggesting that there could be a window time between entinostat administration
and NK cell infusion. Furthermore, we showed that 48 h but not 24 h of treatment
with entinostat down-regulated NK cell receptor expression including: NKG2D,
NKp30, NKp44, and NKp46 (figure 6). Therefore, we elected to administer
entinostat and NK cells 24 h apart to minimize the effect of entinostat on NK cell
receptor expression (Table 2).
At the end of treatment, mice were sacrificed and lungs were preserved for
analysis. Contrary to our initial hypothesis, our findings showed that combining oral
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administration of entinostat with NK cell therapy showed no therapeutic effect for
OS lung metastasis. The combination therapy did not reduce either the number or
the size of nodules in the lung (Figure 17,18).

Table 2. Experimental plan for combination therapy with entnostat and NK
cells in mice with OS lung metastasis. Mice were treated with entinostat at a
concentration of 5 mg/kg of weight by oral/gavage three times a week (Monday,
Thursday, and Saturday) for five weeks. 50 x 106 NK cells were injected via tail
vein two times in a week (Tuesday, and Friday) for 5 weeks.
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Figure 16. Schematic of experimental plan for in vivo study. Nude mice were
injected with 2 × 106 LM7 cells through tail vein. Presence of micrometastasis was
confirmed by H&E staining five weeks after tumor cell infusion. Treatment was
initiated on week six with DMSO, NK cells+ DMSO, entotstat, or entinostat+ NK
cells for five weeks.

Figure 17. Representative pictures of lungs from each mouse group after 5
weeks of treatment. Nude mice were injected via tail vein with 2 × 106 LM7 cells.
Following micro metastasis formation mice were treated with DMSO, NK cells+
DMSO, entinostat, or entinostat+ NK cells for five weeks. Mice were sacrificed,
their lungs were resected and analyzed for the presence of metastasis.
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Figure 18. Combination therapy with NK cells and entinostat did not have
therapeutic effect in mice with stablished OS lung metastasis. Nude mice
were injected i.v. with 2 × 106 LM7 cells. Following micrometastasis formation mice
were treated with DMSO, NK cells+ DMSO, entinostat, or entinostat+ NK cells for
five weeks. Mice were sacrificed and lungs were resected. (A) Number of visible
nodules in each mouse was quantified and the mean number of metastatic nodules
was calculated for each group. (B) Diameter of each individual visible nodule was
recorded and the area of all nodules in each lung was calculated. The results are
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indicated as mean metastatic area of the nodules in each treatment group. Number
of mice per groups= 12-16. Data= mean +/- S.E.M.

The second in vivo study showed that NK cell therapy combined with the
oral administration of entinostat had no therapeutic effect on OS lung
metastasis.
It is known that efficacy of immunotherapy for cancer is highly dependent
on the effector to target cell ratio and that immunotherapy is mostly effective on
minimal residual disease. The sooner we apply the immunotherapy the more
chance of response. In order to monitor onset of micrometastasis formation in the
lung more precisely, we used a genetically modified LM7 OS cell line that
expresses firefly luciferase. We monitored tumor burden in the lungs by
bioluminescent imaging (BLI). Mice were examined on a weekly basis and when ≥
75% of the mice were positive for micrometastasis, they were evenly distributed
into four groups and were treated with DMSO, entinostat, NK cells+ DMSO, or
entinostat+ NK cells for five weeks (n=12/ group). Tumor burden was assessed by
BLI the day before treatment and 5 weeks after treatment (figure 19). Relative fold
increase in the flux was compared between the groups. Similar to our first study,
our results indicated that combination therapy with NK cells and entinostat had no
therapeutic effect on OS lung metastasis and did not reduce the tumor burden in
the lung (figure 20). Furthermore, overall survival of mice treated with entinostat
and NK cells was not improved (figure 21). No significant differences were
observed in overall survival between mouse groups.
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Figure 19. Tumor burden assessed by BLI before (A) and after five weeks of
treatment (B). Nude mice were injected via tail vein with 2 × 106 LM7-Luc cells.
Mice were monitored for micro metastasis formation in the lung every week. When
micrometastasis were observed in 75% of mice, they were evenly distributed into
four groups. Treatment was initiated with DMSO, NK cells+ DMSO, entinostat, or
entinostat+ NK cells for five weeks. Before treatment and at the end of treatment
tumor Burden was assessed by BLI using the IVIS spectrum system.
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Figure 20. Combination therapy with NK cells and entinostat did not have a
therapeutic effect on mice with established OS lung metastasis. Nude mice
were injected via tail vein with 2 × 106 LM7-Luc cells. Following micrometastasis
formation treatment was initiated with DMSO, NK cells+ DMSO, entinostat, or
entinostat+ NK cells for five weeks. Tumor burden was evaluated by BLI before
treatment and after 5 weeks of treatment and then mean relative fold increase in
the flux was calculated for each group.
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Figure 21. Overall survival of mice treated with entinostat and NK cells were
not improved. Nude mice were injected i.v. with 2× 106 LM7-Luc cells. Following
micrometastasis formation mice were treated with DMSO, NK cells+ DMSO,
entinostat, or entinostat+ NK cells for five weeks. Long term survival was assessed
from the day that treatment was initiated until the mice died.

Entinostat increased MICA/B expression on OS lung metastasis.
To determine whether entinostat up-regulated MICA/B expression on OS
lung metastasis, tumor sections from our in vivo experiment were analyzed by
immunohistochemistry staining for MICA/B. Our results showed that MICA/B
expression was significantly up-regulated in mice treated with entinostat or
entinostat+ NK cells (figure 22). Before, we showed that entinostat significantly
increases MICA and MICB mRNAs in OS lung metastasis (figure 14). These
results are consistent with our in vitro findings (figure 1, 2).

68

Negative control

DMSO

NK cells

Entinostat

Entinostat+ NK cells

69

Figure 22. Entinostat increased MICA/B expression on OS lung metastasis.
(A) Paraffin-embedded lung tissues were analyzed for MICA/B expression using
immunohistochemistry staining. (B) Mean PD-L1 positivity was calculated in 5
random fields per section using the Simple PCI software.

Infused NK cells can infiltrate into the mouse lung but do not penetrate into
the lung tumor nodules.
In order for NK cells to have a therapeutic effect, they must reach the target
organ and penetrate into the tumor nodules. Having shown that combining NK cell
therapy and oral administration of entinostat had no therapeutic effect in mice with
OS lung metastasis, we first examined whether injected NK cells can traffic to the
lungs. For addressing this question, nude mice were injected via the tail vein with
50 x 106 CM-DiL-labeled NK cells. At 50 min and 24 h after NK cell injection, the
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mice were euthanized and lungs were removed. Frozen sections of the lungs were
examined under a fluorescent microscope. High numbers of NK cells were present
in the lung 50 min after injection; however, by 24 h after injection there were very
few NK cells left in the lung (figure 23). This data confirmed that NK cell can traffic
into the mouse lungs but either exit or die within 24 h.

Control

50 Minutes after
NK cells injection

24 h after
NK cells injection

Figure 23. Infused NK cells can infiltrate into the mouse lungs. Nude mice
were injected via tail vein with 50x106 CM-DiL-labeled NK cells. Fifty minutes and
24 h post injection, mice were sacrificed and lungs were resected. The frozen
sections of the lung tissues were stained for nucleus using Hoechst 33342 nucleic
acid stain. In vitro NK cells labeled with CM-DiL were examined under the
microscope to confirm that NK cell staining had been successful (top row).
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We further investigated whether following migration to the lungs, NK cells
also penetrated into the OS lung metastasis. Tumor sections from our in vivo
experiment were analyzed by immunofluorescence staining for NK cells. As shown
in figure 24, NK cells were observed at the border of the nodules, but not inside
them. Therefore, the lack of therapeutic effectiveness of combination therapy may
be due to the inability of the NK cells to infiltrate into OS lung metastasis.

Control

Mouse 1

Mouse 2

Figure 24. Infused NK cells did not infiltrate into the OS lung metastasis.
Representative pictures of NK cells in OS lung metastasis from mice treated with
NK cells in combination with entinostat. Frozen sections of the tumor nodules were
stained for the NK cell marker NKp46 and was examined using a fluorescent
microscopy. Ex vivo expanded NK cells were stained for the NKp46 marker to
confirm that staining had been successful (top row).
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Entinostat increased PD-L1 expression on OS cells in vitro.
To further investigate why our combination therapy was not effective against
lung metastasis, we examined whether entinostat treatment increased expression
of programmed death-ligand 1 (PDL-1) on OS cells. PDL-1 is a ligand for the
programmed death 1 (PD-1) receptor which is an immune inhibitory receptor
expressed on immune cells, including NK cells. Interaction between PD-1 and
PDL-1 induces an immune suppressive effect on immune cell and allows tumor
cells to escape from immune cell mediated killing (11).
LM7 and CCH-OS-D cells were treated with various doses of entinostat for
24 h and expression of PDL-1 was evaluated by flow cytometry. Results
demonstrated that PDL-1 expression is upregulated on LM7 and CCH-OS-D cells
in a dose dependent manner, suggesting a mechanism by which OS metastasis
can escape from NK cell therapy (figure 25).
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Figure 25. Entinostat increases PD-L1 expression on OS cells in a dose
dependent manner. LM7 and CCH-OS-D cells were treated with 0.1, 0.5, 1.0, or
2.0 µM entinostat for 24 h. Cells were stained for PD-L1 and were analyzed by flow
cytometry. Untreated cells were used as control.

Ex vivo expanded human NK cells express PD-1.
To verify that the NK cells used for the animal studies expressed PD-1, we
purified human NK cells from heathy donors’ buffy coats and expanded them in
vitro for three weeks, as described earlier. PD-1 expression was then analyzed by
flow cytometry. As it is shown in figure 26, approximately 6-8% of ex vivo expanded
NK cells express PD-1.

Figure 26. Ex vivo expanded human NK cells express PD-1. Flow cytometry
analysis for PD-1 expression on expanded NK cells. Human NK cells were purified
from buffy coats and were expanded in vitro for three weeks using genetically
engineered K562 and recombinant human IL-2. Cells were stained for PD-1 and
expression of receptor was analyzed by flow cytometry.
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SUMMERY
Our in vivo findings demonstrated that combination therapy with entinostat and NK
cell had no therapeutic effect on OS lung metastasis in our mouse model. This
result is in contrast with our in vitro data showing that OS cells are sensitive to NK
cell killing and that entinostat enhances OS cell susceptibility to NK cell-mediated
cytotoxicity. We also showed that although infused NK cells infiltrate into the lung,
they are not able to penetrate into the tumors. Further, by showing that entinostat
increased PD-L1 expression on OS cells in vitro, we proposed an additional
mechanism of escape by tumor cell by interacting with the PD-1 receptor on NK
cells and inducing inhibitory signals.

75

DISCUSSION

Chapter 7
Discussion: Implications of Results and Future Directions
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There has been no improvement within the past 25 years in the 20% 5-year
survival rate for patients with OS lung metastasis. Disease relapse with pulmonary
metastasis continue to be the major causes for death (1). Poor survival rates for
patients who present with pulmonary metastasis highlights the necessity of new
therapeutic strategies. Boosting the patient’s own immune system is one such
option. Our group has previously showed that IL-11Rα specific CAR-T cells
resulted in regression of lung metastasis in IL-11Ra overexpressing osteosarcoma
tumors (9).Though the CAR T cells exhibited anti-tumor efficacy, there is a risk of
organ toxicity since the targeted antigen is expressed on normal cells i.e. liver and
endothelial cells. NK cell mediated immunotherapy is emerging as a promising
therapeutic strategy for cancer as NK cells exhibit antigen independent cytolytic
activity so that normal cells can be spared.
Our group had previously shown that aerosol IL-2 given in combination with
NK cell therapy significantly augmented the antitumor efficacy of NK cells for OS
lung metastasis. Adding aerosolized IL-2 to NK cell therapy decreased the tumor
burden in the lung dramatically and improved the overall survival of mice; however,
this therapy failed to eliminate tumors completely from the lungs (46, 47). Some
novel strategies are needed to improve the overall survival of patients with OS
pulmonary metastasis. Our focus has been to further augment the therapeutic
efficiency of NK cell therapy. The main goal of this thesis is to investigate the role
of entinostat, an HDAC inhibitor, on the efficacy of NK cell-mediated
immunotherapy using our human OS pulmonary metastasis mouse model.
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Entinostat sensitize OS cells to NK-cell mediated cytotoxicity by increasing
ligands for activating NK cell receptors
NKG2D is a primary activating receptor expressed by NK and T cells
against tumor targets. NKG2D interacts with target cell ligands heterogeneously
expressed on tumor cells including MHC-class 1 related genes MICA and MICB
and UL16-binding proteins (ULBP-1 through 6). These cell ligands are upregulated
in response to cellular stress, however tumors may escape NK cell recognition by
either suppressing NKG2RD receptor expression or by down regulating their ligand
expression (80, 81).
Our group along with others showed that OS cells are susceptible to NKcell mediated cytotoxicity due to the high expression of ligands for NK cell
activating receptors (32, 45, 46). The aim of this study was to augment the efficacy
of NK cell therapy against OS pulmonary metastasis by up-regulating NK cell
ligands on the tumor cells. It is known that besides the immediate inhibitory effects
of HDAC inhibitors on tumor growth, they also enhance recognition of tumor cells
by immune cells (80). Our data showed that entinostat up-regulated expression of
ligands specific for NK cell activating receptors (MIC A/B, ULBP1, ULBP2/5/6, and
CD155) in OS cell lines (chapter 2, figure 1). Protein and mRNA levels of MICA
and MICB were upregulated in a dose and time dependent manner consistent with
our previously published results (58). Expression of up-regulated ligands on OS
cells was stable for more than 24 h after drug removal from the culture (chapter 2,
table 1); this provide an evidence that there would be sufficient time for NK cells
to recognize and kill tumor cells in our mouse model.
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Our laboratory demonstrated in vitro that NK cell mediated cytotoxicity is
directly correlated with the number of NKG2D ligands expressed on OS cells, e.g.
KRIB cells were less sensitive to NK cell lysis than LM7 and CCH-OS-D cells due
to their lower level of NKG2D ligands expression (46, 47). In this study we showed
that up-regulation of NK cell ligands on OS cell lines by entinostat increased their
susceptibility to NK cell-mediated cytotoxicity, and that the NK cell function was
abrogated by NK cell receptor blockade (chapter 2, figure3, 4). Our results are in
agreement with many other’s published data. Burghuis et. al., demonstrated that
HDAC inhibitors, including entinostat, increased the susceptibility of Ewing
sarcoma cells for NKG2D-dependent cytotoxicity by NK cells (59). Schmudde et.al
showed that the HDAC inhibitors SAHA, sodium butyrate, and entinostat treatment
increased the susceptibility of prostate carcinoma and medulloblastoma cell lines
for NK killing using the same mechanism (60). These results are also in
accordance with published data concluding that HDAC inhibitors increase the
susceptibility of tumor cells to NK cell-mediated cytotoxicity by increasing the
expression of MICA/B (61-63). These finding suggest that sensitizing OS cells for
NK cell killing by HDAC inhibitors may be an approach to improve the efficacy of
NK cell immunotherapy.

79

Effect of entinostat on NK cell viability, receptor expression, and cytotoxic
function
Although increased expression of NK cell ligands on OS cells with entinostat
treatment resulted in enhanced tumor recognition and lysis, the adverse effects of
the drug on NK cells might diminish this benefit. To evaluate this possibility, we
examined the effect of entinostat on NK cell viability, receptor expression, and
cytotoxic function. Our findings demonstrated that entinostat was not cytotoxic for
NK cells and did not affect their viability within 48 hours of treatment (chapter 3,
figure 5). Previous studies indicated that even low dose of entinostat (0.1 μM)
increased NKG2D expression on freshly purified human NK cells (58). Here we
showed that exposure to ≤ 2 µM of entinostat for 24 h resulted in no change in ex
vivo expanded NK cell receptor expression (NKG2D, NKp30, NKp44, NKp46, and
DNAM-1). However, after 48 hours, higher doses of the drug (≥ 0.5 µM) downregulated NK cell receptors expression except for the DNAM-1 (chapter 3, figure
6). Based on these findings, the in vivo study was designed in which the
administration of the drug and infusion of NK cells were at least 24 hours apart to
avoid down-regulation of NK cell receptor expression.
Importantly, our data demonstrated that 24 hours pretreatment with
entinostat did not affect the NK cell-mediated cytotoxicity against OS cells (chapter
3, Figure 7). Contrary to our results, Ogbomo et al., showed that VPA (a broadspectrum class I- and IIa-specific HDACi) and SAHA (a pan-HDACi) suppressed
NK cell lytic activity (77). However, they did not include entinostat in their study.
The differences in the reported effect of HDAC inhibitors on NK cells may be
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explained by the relative specificity of HDAC inhibitors for various HDAC isoforms
and their ability to inhibit the function of a specific HDAC. Ogbomo et al., used
freshly purified NK cells from blood buffy coats in their study. By contrast we used
activated ex vivo expanded NK cells. Presently, the exact mechanism involved for
the disparity between two studies is unclear. In conclusion our findings suggest
that combining entinostat with NK cell therapy should not interfere with NK cellmediated cytotoxicity.

Entinostat’s mechanism of action and its regulation of MICA/B expression in
OS cells
We proposed two mechanisms by which entinostat up-regulates MICA/B
expression in OS cells (figure 27). As an HDAC inhibitor, entinostat promotes
activation of gene transcription by inducing histone acetylation on chromatin. We
demonstrated that entinostat may increase MICA and MICB gene transcription by
acetylation of histone 4 linked to the MICA and MICB gene promoters; but not
through enhancing acetylation of histone 3 (chapter 4, figure 9). This may be
unique to OS cells as previous reports showed that treating colon carcinoma cells
with entinostat resulted in up-regulation of MICA and MICB expression by
acetylation of histones 3 linked to MICA and MICB gene promoters (58). The
histone deacetylase inhibitor SAHA has also been shown to enhance MICA/B gene
transcription by increasing MICA-associated histone acetylation (78).
The second mechanism we investigated for up-regulating MICA and MICB
expression is the role of miRNAs i.e miR-20a, miR-93, and miR-106b (73). Our
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data showed that these 3 miRNAs down-regulated MICA and MICB expression in
OS cells (chapter 5, figure 10, 11). We further demonstrated that down-regulation
of MICA and MICB expression by miR-20a, miR-93, and miR-106b is not controlled
by MICA and MICB mRNA degradation. We are the first to show that entinostat
leads to the up-regulation of MICA/B by down-regulating miR-20a, miR-93, and
miR-106b in OS cells in vitro and in vivo (figure 12). Similarly, it has been
demonstrated that SAHA upregulates the transcription of MICA/B by suppressing
the MICA/B-targeting miRNAs miR-20a, miR-93 and miR-106b in hepatocellular
carcinoma (78).
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Figure 27. Mechanisms by which entinostat increases MICA/B expression in
OS cells. Entinostat increases the accumulation of acetylated histone 4 in
chromatin linked to both MICA and MICB genes and results in MICA and MICB
gene up-regulation. Entinostat also increased MICA and MICB expression by
down-regulating mir-20a, mir-93, and mir-106b expression in OS cells.
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NK cell therapy in combination with entinostat in mice with OS pulmonary
metastasis
Clinical data suggest that NK cells may have a role in OS prevention and
prognosis. For example, study on children with OS showed that they had fewer
number of peripheral NK cells compared to the control group. This suggests a role
for NK cells in preventing OS (42). OS patients who had early lymphocyte recovery
(including NK cells) after chemotherapy showed better prognosis than patients with
late lymphocyte recovery (43). Further, OS patients treated with IL-2 in addition to
chemotherapy had higher number of NK cells and the degree of the NK cell activity
and the number of NK cells significantly correlated with the clinical outcome (82).
Having demonstrated that entinostat increases the susceptibility of OS cells
to NK cell lysis in vitro (described in Chapter 2), we next determined whether
entinostat in combination with NK cell infusion enhances the anti-tumor efficacy of
NK cells in a nude mouse model with established OS pulmonary metastasis.
Contrary to our in vitro findings, our results showed that combining oral
administration of entinostat and NK cells infusion did not decrease the tumor
burden in the lungs (chapter 6, figure 18).
Having shown that ex vivo expanded NK cells used for immunotherapy were
fully activated and highly cytotoxic to LM7 cells (chapter 6 figure 15), it is unlikely
that the ineffectiveness of NK cells to eliminate the tumor cells in vivo was due to
their impaired function. Further, we demonstrated that the sub-therapeutic dose of
entinostat (5 mg/kg) used was enough to significantly increase NKG2D ligand
(MICA and MICB) expression on OS lung metastasis (chapter 6 figure 14, 22).
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Taken together, these data indicate that entinostat had done its predicted role in
our therapy.
The efficacy of immunotherapy for cancer is highly dependent on the
effector to target cell ratio. Thus, for the second animal study we used genetically
modified OS cell line LM7 expressing firefly luciferase to be able to monitor
micrometastasis formation in the lungs by bioluminescent imaging and initiate
therapy at the earliest time. We started the treatment when >75% of the mice
developed micrometastasis, and we observed similar results as the first animal
study (chapter 6, figure 20). This result indicates that the therapy’s ineffectiveness
was probably not secondary to high tumor Burden.
In order for NK cell therapy to be effective, the cells must reach the target
organ (lung) and penetrate into the tumor. We showed that infused NK cells are
able to traffic to the mouse lungs. However, these NK cells failed to infiltrate into
the lung nodules to eliminate the tumor cells (chapter 6 figure 23, 24). This may
explain why entinostat together with NK cells had no additive effect on tumor
regression. In addition to this, the presence of immune suppressive cells and/or
absence of activating and chemotactic factors in tumor microenvironment may
have played a role in the lack of therapeutic effect by NK cells.
Ex vivo activated NK cells have a limited survival time and show low tumor
penetration without cytokine support in vivo (83, 84). IL-2 promotes activation,
proliferation and survival of NK cells, resulting in enhanced cytotoxic function for
numerous different tumor cells (85). Most of the clinical trials of adoptive NK cell
therapy use the subcutaneous administration of IL-2 to patients (31, 86, 87). Our
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research group used aerosol IL-2 in combination with NK cells to increase their
anti-tumor efficacy to OS lung metastasis and to avoid the significant side effects
that accompany systemic IL-2 administration (46, 47). Aerosol IL-2 dramatically
increased the number of infused NK cells in the metastatic pulmonary nodules
resulting in increased tumor regression and improved overall survival of mice
compared to those treated with NK cells alone. Another study also showed that NK
cell immunotherapy decreased the tumor burden in the tibia, reduced bone
damage, and raised the overall survival in NSG mice with OS lung metastasis only
when IL-2 (10,000 IU IP injection /mouse) was added to the therapy (45). All these
results suggest that adding IL-2 cytokine support to entinostat and NK cell
combination therapy may be beneficial for the persistence in the lung, penetration
into the tumor and enhanced cytotoxic function of infused NK cells in vivo. This is
even more crucial in our mouse model in which the crosstalk between NK cells
and T cells is absent due to the lack of T cells in nude mice. T cell interaction with
other immune cells including NK cells enhance immune response against tumors.
CD4+ T cells are known to be the main source for IL-2 production and tumor
antigen-specific CD8+ T cells has been shown to provide stimulatory signals for
NK cells in the tumor microenvironment setting (88, 89). In conclusion, although
we demonstrated that entinostat increased the expression of NK cell ligands on
OS lung metastasis, this may not have been enough to augment the efficacy of NK
cell therapy due to the absence of factors (such as cytokines and chemokines)
augmenting NK cell proliferation and survival in the tumor microenvironment.
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Combining NK cell therapy with cytokines such as IL-2 or IL-21 may provide the
needed additional support.
It is well known that tumor cells can induce immune escape mechanisms
(90). Many tumors down-regulate or internalized their NKG2D ligands (91) or
reduce MICA and MICB surface levels by ligand proteolytic shedding from the cell
surface (92-94). Reduced expression of MICA and MICB on the tumor cell surface
and increased levels of their soluble forms in the tumor microenvironment and
serum can impair NKG2D-mediated cytotoxicity of NK cells. High levels of soluble
MICA (sMICA) in OS patient’s serum has indeed been detected (95). In another
study serum and tumor biopsies from OS patients before radiotherapy and
chemotherapy showed high expression levels of MICA (96). Very high serum
levels of sMICA were detected in one third of the patients but not in healthy controls
and elevated sMICA levels were associated with the disease progression and rate
of metastasis. Therefore, in our mouse model the proteolytic shedding of MICA
may also have interfered with NK cell cytotoxicity. Future studies investigating this
aspect might are warranted.
PD-L1 up-regulation on tumor cells contributes to tumor immune-escape
(97, 98). Interaction between the PD-1 receptor, expressed on immune cells, and
its ligand PD-L1, expressed on tumor cells, leads to immune cell anergy, and
apoptosis and allows tumor cells to escape from immune-mediated cytotoxicity.
Blockade of the PD-1/PD-L1 interaction in patients with solid tumors lead to
improved clinical outcome (99, 100). PDL-1 has been reported to be expressed on
OS cell lines as well as OS tumor samples (101-104). Blocking PD-1/PD-L1 axis

87

in K7M2 mice with OS pulmonary metastasis resulted in enhanced T cell
cytotoxicity, tumor regression and improved survival. However the impact of PDL1 blockade on NK cell function has not been studied in this mice model (103).
Our in vitro data demonstrated that entinostat upregulated PD-L1 expression on
OS cell lines in a dose dependent manner (figure 25); approximately 6-8% of ex
vivo expanded NK cells expressed the inhibitory receptor PD-1 (figure 26). Hence
we proposed that up-regulation of PD-L1 on metastatic OS by entinostat may
compromise tumor reactive PD-1+ NK cell function leading to reduced anti-tumor
effect. However, we have not determined the level of PD-L1 on OS lung metastasis
following the infusion of NK cells in vivo.
Malignant cells can also interfere with anti-tumor efficacy by producing
immune suppressive factors such as TGF-β, IL-10, and Macrophage Migration
Inhibitory Factor (MIF), or by recruiting immunosuppressive leukocytes such as
myeloid-derived suppressor cells (MDSCs) and regulatory T cells into the tumor
microenvironment (90, 105). TGF-β1 secreted by tumor cells can down-regulate
NKG2D and NKp30. Overexpression of MIF on ovarian cancers is associated with
the down-regulation of NKG2D on NK cells (106-109). Investigating the effect of
TGF- β and MIF on NK cell functionality in our in vivo studies might provide insight
for the reduced anti-tumor effect in mice.
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Conclusions
The immune system is a critical regulator for controlling cancer growth. Adoptive
immunotherapy is a promising approach to combat cancer. However, cellular
immunotherapy including NK cell therapy seems to be more challenging in patients
with solid tumors. In this study we demonstrated that HDAC inhibitor, entinostat,
augmented NK cell-mediated cytotoxicity for several different OS cell lines by upregulating the ligands specific for NK cell activating receptors. Up to 2 μM
entinostat for 24 hours did not change NK cell viability, or the activating receptor
expression and function. We also demonstrated two possible mechanisms by
which entinostat increases NKG2D ligands (MICA and MICB) in OS cells, first by
increasing histone 4 acetylation on the MICA and MICB gene promoters, and
second by down-regulating mir-20a, mir-93, and mir-106b expression. We did not
observe significant differences in the tumor burden in mice treated with entinostat
plus NK cells compared with entinostat or NK cells alone. Our data suggest that
the reason for the lack of a therapeutic effect is secondary to the failure of the NK
cells to traffic into the tumor nodules. Although, NK cells migrated into the lung, we
only observed NK cells at the periphery of the tumor and not in the center.
Entinostat treatment also resulted in up-regulation of immune inhibitory
molecules PD-L1 on OS cell lines. Thus, blockade of PD/PDL1 axis with PD-L1
monoclonal antibodies may improve the anti-tumor effect of NK cells against the
OS lung metastasis. More studies are needed to reveal the mechanism of
resistance.

89

FUTURE DIRECTIONS

Enhancing NK cell infiltration and retention in osteosarcoma lung metastasis
by aerosol IL-2 or IL-21 administration
Our data demonstrated that treating OS cells with entinostat up-regulated
the expression of NK cell activating ligands on OS cells and increased NK cellmediated cytotoxicity in vitro. However, while the oral administration of entinostat
also resulted in increased ligand expression in vivo, combination therapy did not
augment the efficacy of NK cell therapy against OS lung metastasis. One of the
reasons could be the inability of infused NK cells to infiltrate into the OS lung
nodules. We observed the infused NK cells only at the periphery of the tumors.
Since NK cells are highly dependent on cytokine milieu support like IL-2 and IL-21
for their function, proliferation, and retention in the tumor microenvironment, we
propose that adding a stimulatory cytokine to the treatment may increase the
efficacy of NK cell therapy with or without entinostat. This would create a dual
effect, i.e. increases the susceptibility of OS cells to NK cell-mediated killing by
enhancing the expression of NK cell ligands and increasing NK cell efficacy by
increasing the penetration of the NK cells dipper into the tumor tissue.
To avoid the side effects of systemic IL-2 administration and to activate the
injected NK cells in the lung specifically, we propose using aerosol IL-2 delivery.
To assess this, nude mice would be injected i.v. with 2 x 106 LM7 cells to establish
micrometastasis in the lungs. A similar treatment schema that we used in our study
will be followed with the exception of adding of aerosol IL-2 administration (mice
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groups: aerosol IL-2; NK cells+ IL-2; entinostat+ IL-2; or NK cells+ entinostat+ IL2). For example, recombinant human IL-2 will be given at 2000 U/mouse three
times a week for five weeks (Table 3). The safety of aerosol IL-2 has been reported
both in clinical trials and in our mouse model as well as in immunocompetent
BALB/C mouse (46, 110, 111). We have previously demonstrated that no acute or
chronic inflammation, toxicity, elevated liver enzymes or abnormal CBC was seen
following aerosol IL-2 administration, supporting the concept of using organspecific delivery as a way to treat lung metastasis (46, 47).
After 5 weeks of treatment, the number of visible nodules would be
quantified and the weight of lungs will be compared with the control group in order
to evaluate the therapeutic effect of combination therapy. Paraffin-embedded OS
lung metastasis tissues will be stained for the NK cell marker NKp46 to assess the
number of infiltrated NK cells in the lung nodules. We anticipated that aerosol IL-2
will result in increased NK cells inside the tumor nodules. The correlation between
the number of NK cells in the lung nodules and the tumor apoptosis (using TUNEL
staining) will be assessed. We anticipated that increased NK cell content will
correlate with increased apoptosis. Survival will also be evaluated. We predict that
aerosol IL-2 therapy will enhance infiltration, and retention of NK cells in tumors
resulting in decreased tumor burden in the lungs and improved survival.

91

Table 3. Experimental plan for combination therapy with entnostat, NK cells
and aerosol IL-2 in mice with OS lung metastasis. Mice will be treated with
entinostat at a concentration of 5 mg/kg of weight by oral/gavage three times a
week (Monday, Thursday, and Saturday) for five weeks. Recombinant human IL2 will be given by aerosol delivery at 2000 U/ mouse three times (Monday,
Thursday, and Saturday) for five weeks. 50x 106 NK cells will be injected via tail
vein two times in a week (Tuesday, and Friday) for 5 weeks.

Another alternative for increasing NK cell infiltration into the OS lung
metastasis is the use of Interleukin‑21 (IL-21). This cytokine is mostly produced
by NKT, CD4+ T, and Th17 cells. IL-21 regulates T, B, and NK cells function (112).
The antitumor activity of IL-21 has been shown in various preclinical investigations
(113-115). In clinical trials, the safety and efficacy of IL-21 has been demonstrated
for metastatic melanoma and renal cell carcinoma (116-118). Furthermore, it has
been shown that IL-21 stimulated NK- and CD8+ T cell-mediated cytotoxicity
against mantle cell lymphoma, and renal cell carcinoma in vivo (119, 120). In
addition, tumor regression in mice bearing fibrosarcoma or melanoma after
treatment with IL-21 was dependent on NK cell-mediated cytotoxicity rather than T
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cell cytotoxicity (121). These findings suggest that adding IL-21 to our treatment
may enhance the efficacy of NK cell therapy with or without entinostat. In the latter
study, injection of a plasmid DNA encoding murine IL-21 resulted in increased and
constant expression of IL-21 in the blood (121). Murine IL-21 plasmid can be
administered through tail vein injections and the maximum tolerable DNA dose
would be determined in our mouse model as previously described (122, 123). The
volume of the DNA solution and number of injections will be optimized. Based on
the method used in the previous studies, various amounts of plasmid in 1-3 ml of
saline within 5-7 second will be administered (121-123). More than one injection
per mouse may be needed to gain the maximum plasmid DNA expression in
hepatocytes.
After optimizing the conditions for plasmid administration, we would follow
the same treatment schema that we used for aerosol IL-2 but would substitute
systemic IL-21 plasmid DNA. After 5 weeks of treatment, mice will be sacrificed
and lungs will be weighed and examined for the number of nodules. The number
of infiltrated NK cells and its correlation with the tumor cell apoptosis and
regression will be evaluated as well. The presence of organ cytotoxicity and
elevated liver enzyme levels due to IL-21 administration will also be assessed. We
expect that administration of IL-21 would result in increased number of NK cells in
the OS lung tumors along with the enhanced NK cell anti-tumor effect as
demonstrated by increased tumor cell apoptosis, decreased numbers and size of
lung metastasis and an improved survival rate.
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The limitations of these studies is our nude mouse model which does not
exactly mimic the human clinical setting due to absence of T cells. T cell crosstalk
with other immune cells including NK cells has been shown to enhance the
immune response against tumors. For example, T cells secrete cytokines such as
IL-2 and IL-21 that play an important role in NK cell activation. IL-2 activates both
cytotoxic T and immunosuppressive regulatory T cells (124). Although, activation
of regulatory T cells is not a concern in our nude mouse model, this can be a
limitation for IL-2 administration in a clinical setting.
Crosstalk between macrophages and NK cells may also play a role in NK
cell-mediated tumor regression. Tumor-associated macrophages (TAMs) are
known to be the most dominant immune cells in the tumor microenvironment (125).
M1 and M2 macrophages are two subtypes of macrophage with completely
different functions in the tumor setting. In the initial phase of tumor development,
the tumor microenvironment induces the polarization of TAMs toward the M1
phenotype while the M2 phenotype is dominant during tumor progression (126).
By producing Th1-type cytokines, e.g. IL-12 and TNFα, M1-polarized
macrophages induce anti-tumor responses. In the Th1/M1-polarizing context,
interaction between different immune cells like macrophages, DCs, and
neutrophils results in NK cells activation and enhanced anti-tumor effect.
Alternatively, activated NK cells may further promote activation of other immune
cells such as macrophages, T cells, and DCs and enhance Th1/M1 polarization
(19, 127-131). In contrast, M2-polarized TAMs enhance tumor progression by
producing immunosuppressive cytokines (TGF-ß and IL-10) and promote
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angiogenesis, stroma formation, tissue reconstruction, and metastasis. High
numbers of M2-polarized macrophages in the tumor microenvironment may
correlate with the tumor progression and poor prognosis (132) and may also
contribute to the inability of NK cells to penetrate into the tumor due to the stoma
formation. Since nude mice do have macrophages this may have contributed to
the inability of NK cells to migrate into the lung tumors.
In our in vivo studies, administration of aerosol IL-2 may activate mouse NK
cells in the lung nodules since mouse NK cells can be activated by human IL-2
(46, 133). Activated NK cells may produce cytokines and immune stimulatory
factors (INF- γ, TNFα, GM-CSF, and MIP-1) that induce M1 polarization. To
investigate this possibility, IHC staining for M1 and M2 TAMs on OS lung
metastasis samples may be performed using their markers CD86 and CD163,
respectively. Flow cytometry of dissociated tumor cells stained with antibodies
specific for M1 and M2 would also be performed. It would be important to evaluate
if entinostat has any modulatory effect on macrophage and the ratio of M1 and M2
macrophages in our mouse model. Interestingly, higher number of macrophages
in the pretreated biopsies of patients with OS correlated with longer overall survival
and fewer metastasis (134). These findings suggest a rationale for using
macrophage activating agents such as L-MTP-PE in patients with OS. Combining
L-MTP-PE with the standard chemotherapy resulted in a 29% decrease in mortality
rate in newly diagnosed OS (15) and significantly increased the disease-free
survival rate in relapsed OS patients (14). Therefore, using L-MTP-PE together
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with other immune therapies which increases macrophage infiltration into the lung
metastasis may be beneficial.

Investigating the interference of soluble forms of MICA and MICB with the
NK cell therapy in mice with OS lung metastasis
Stress-inducible MICA and MICB ligands are heterogeneously expressed
on tumor cells. Many tumors escape from the immune system by proteolytic
cleavage of the ligands and releasing the soluble forms of MICA, MICB (sMICA
and sMICB) or other NKG2D ligands (135-138). The process of ligand shedding
results in decreased expression of MICA and MICB on the tumor cell surface and
increased soluble forms in the serum and microenvironment, which in turn can
impair NKG2D-mediated cytotoxicity of NK cells and cytotoxic T lymphocytes.
Recently, the presence of soluble forms of NKG2D ligands has been demonstrated
as a prognostic factor and diagnostic biomarker for cancer (139, 140). In fact, the
mechanisms involved in the release of these ligands from the cell membrane are
considered as potential targets to be blocked with the goal of increasing the
efficacy of antitumor immunity.
Elevated levels of MICA in the serum of OS patients are correlated with the
stage of the disease and rate of metastasis. Further, MICA expression on OS
tissues was adversely correlated with the stage of the disease (95, 96). Previous
studies demonstrated that Matrix metalloproteinase 9 (MMP9) may be responsible
for MICA shedding from the OS cell surface (141) and other tumors (142). Down-
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regulation of MMP9 resulted in reduced MICA cleavage from OS cells (143, 144).
MMPs are over-expressed in many tumor cells and clinical trials are underway
using MMP-inhibitors in cancers. MMPs consist of 24 human zinc-binding
endopeptidases that play different roles in tumor cell growth, survival, invasion,
and migration (145). Proteolytic cleavage by MMPs is known to be the main
mechanism involved in the release of MICA, MICB, and ULBP2 from the cell
membrane (146).
Thus, it would be interesting to investigate the role of sMICA and sMICB in
the NK cell therapy in our mouse model. Valproic acid has been shown to upregulate MICA and MICB expression on OS cells and reduce the sMCA and sMICB
shedding due to the down-regulation of MMP9 expression (143). However, UCI10, an ovarian cancer cell line, released more sMICA and sMICB after being
treated with HDAC inhibitor trichostatin A both in vitro and in vivo (94). The effect
of entinostat on sMICA and sMICB secretion is unknown at present. To investigate
this, sMICA and sMICB levels will be measured in control and entinostat-treated
OS cell culture media by ELISA. Next, NK cells will be mixed with the culture media
of control and entinostat-treated OS cell lines. The cytotoxicity of these two groups
of NK cells against OS cells would be assessed by calcein release assay. Since
the effect of entinostat on MICA and MICB shedding from OS cells is unknown, the
results of these experiments cannot be predicted.
In order to determine whether shedding of MICA and MICB can be reduced
by MMP9 inhibitor and to investigate how this process will be affected by
entinostat, we will treat OS cells with various doses of MMP9 inhibitor with or
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without entinostat treatment. As other studies have shown, we expect that the
inhibitor would reduce the shedding of sMICA and sMICB (94, 143, 144). The
effect of the MMP9 inhibitor on the NK cell-mediated tumor cytotoxicity against OS
cells would be assessed. NK cells will be mixed with the culture media from
untreated or treated OS cells with MMP9 inhibitor and then their cytotoxicity
against OS cells would be evaluated using calcein release assay. We expect that
media from OS cells treated with MMP9 inhibitor would have less ability to block
the NK cell-mediated cytotoxicity due the lower levels of MICA and MICB in the
media.
To assess the in vivo effect, nude mice bearing OS lung metastasis will be
treated with a sub-therapeutic dose of entinostat with or without the MMP9
inhibitor. Serum levels of sMICA and sMICB will be measured in each group. Lung
nodules will be stained for MICA and MICB expression. If we find enhanced MICA
and MICB expression on the lung metastasis and lower levels of sMICA and
sMICB in the serum from mice treated with both entinostat and MMP9 inhibitor,
then we will use the combination of MMP9 inhibitor and entinostat to investigate
whether the inhibitor can increase penetration of NK cells into the tumor and the
efficacy of NK cells in mice established with OS pulmonary metastasis.
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The effect of anti-PD-L1 antibody on the efficacy of combination therapy of
NK cells and entinostat in mice with OS lung metastasis.
PD-L1 up-regulation on tumor cells inhibits the anti-tumor activity of immune cells
by triggering inhibitory signals into the immune cells following PD-L1/PD-1
interaction (11). PDL-1 has been shown to be expressed on OS cell lines as well
as OS tumor samples (101-104). In vitro, we demonstrated that entinostat
enhanced PD-L1 expression on OS cell lines in a dose dependent manner.
However, the effect of entinostat on PD-L1 expression on OS lung metastasis is
unknown at this time. This effect can be investigated by treating nude mice bearing
OS lung metastasis with 5 mg/kg entinostat or DMSO 3 times a week for 2 weeks.
The level of PD-L1 expression on the lung tumors would be determined using IHC
staining and flow cytometry of dissociated tumor cells stained for PD-L1. If our
results show that entinostat up-regulates PD-L1 expression on OS lung
metastasis, we will add anti-PD-L1 to our combination therapy to block the PD1/PD-L1 axis. Using PD-L1 antibody in Balb/cJ mice with OS pulmonary metastasis
resulted in enhanced T cell cytotoxicity, tumor regression and improved survival.
However the impact of PD-L1 blockade on NK cell function has not been studied
in this mouse model (103).
A similar treatment schema as described in the results section will be used
with the addition of anti-PD-L1 (mice groups: control; NK cells; entinostat; PD-L1
mAb; NK cells+ entinostat; NK cells+ PD-L1 mAb; entinostat+ PD-L1 mAb, or NK
cells+ entinostat+ PD-L1 mAb). 200 μg PD-L1 antibody (10F.9G2, BioLegend)
would be administered every three days for five weeks (147). At the end of
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treatment, mice will be sacrificed and lungs will be examined for the number and
size of the nodules. The number of infiltrated NK cells in the lung tumors and its
correlation with the tumor regression will be also determined in each group. PD-L1
expression on lung tumors will be determined by IHC staining. Infiltrated NK cells
into the lung tumors will be isolated and analyzed by flow cytometry to determine
whether the expression of PD-1 is different. If the in vivo results show that
administration of PD-L1 antibody enhances the efficacy of NK cell therapy, then it
would be interesting to create and inject PD-L1 shRNA knockdown LM7 cells into
nude mouse to establish OS metastasis and to investigate the efficacy of NK cell
combination therapy with entinostat in the absence of PD-L1 expression on tumor
cells.
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MATERIALS AND METHODS

Chapter 8
Materials and Methods
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Reagents and antibodies
Entinostat was purchased from Sigma-Aldrich (St. Louis, MO). For in vitro
experiments, entinostat was dissolved in absolute ethanol and then diluted in
Dulbecco’s modified Eagle’s medium (DMEM) for working solutions. For in vivo
experiments, entinostat was dissolved in DMSO. Anti-human acetyl-histone3, antihuman acetyl-histone4, anti- human acetyl-histone H3 antibody, and anti- human
acetyl-histone H4 antibody were purchased from Millipore (Temecula, CA). Antihuman MICA/B was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Cell lines
The metastatic human LM7 OS cell line used in our study was derived from
the parental SAOS-2 cell line by re-cycling the cells 7 times through the lungs of
nude mice. KRIB, CCH-OS-D, and CCH-OS-O OS cell lines were kindly provided
by Dr. Dennis Hughes from MD Anderson Cancer Center. CCH-OS-D and CCHOS-O are primary OS cell lines derived from patient samples at the Children’s
Cancer Hospital at MD Anderson Cancer Center. Cell lines were cultured in DMEM
supplemented with 1% streptomycin/penicillin, 1 mmol/L nonessential amino
acids, 2 mM L-glutamine, 1 mmol/L sodium pyruvate, and 10% fetal bovine serum
(Intergen, Purchase, NJ). All cells were incubated at 37°C with 5% CO2. Cells
were split no more than 4 times before they were injected intravenously (i.v.), and
they were free of mycoplasma.

102

Animals
Four- to six-week-old nu/nu mice were purchased from the National Cancer
Institute Mouse Repository, Frederick, MD, and kept in pathogen-free conditions
in a laminar air flow room as approved by the American Association for
Accreditation of Laboratory Animal Care. Experiments were conducted according
to the animal protocols approved by the Institutional Animal Care and Use
Committee (IACUC).

Human NK cell isolation and expansion
Human NK cells were isolated from healthy donors’ buffy coats. Then they
were expanded in vitro for 4 weeks using genetically engineered K562 and
recombinant human IL-2, as previously described (36). Briefly, NK cells were
purified from blood buffy coats using RosetteSep Human NK Cell Enrichment
Cocktail (Stem Cell Technologies, Vancouver, BC) and buoyant density
centrifugation on Ficoll-Paque (GE Healthcare Life Sciences, Little Chalfont, UK).
Isolated NK cells were seeded with irradiated K562 (100 cGy) at a ratio of 1:2 in
RPMI 1640 medium (Cellgro/Mediatech, Manassas, VA). RPMI was supplemented
with 10% fetal bovine serum (Intergen, Wellington, New Zealand), 2 mmol/L
glutamine , 1 mmol/L sodium pyruvate, and 50 IU/ml recombinant human IL-2.
Every 3 days, half of the NK cells medium was replaced with fresh RPMI and then
fresh IL-2 was added to the entire media. At the end of each week, NK cells were
re-stimulated with irradiated K562 at the ratio of 1:1 and re-suspended in fresh
RPMI plus 50 IU/ml recombinant human IL-2. Four weeks after expansion, NK cells

103

were frozen in freezing medium (FBS+ 10% dimethyl sulphoxide, DMSO) at a
concentration of 5x107 cells/ vial and kept at -80οC for further use. By end of 4weeks of expansion, NK cell purity was ≥98%. Before NK cells were infused into
mice, their viability and receptor expression were evaluated with use of Vi-CELL
and flow cytometry, respectively. Furthermore, to confirm that expanded NK cells
can recognize and lyse LM7 cells, their cytotoxicity against LM7 cells was
evaluated by calcein release assay.

Flow cytometry analysis
NK cell phenotypes were analyzed weekly with flow cytometry using murine
anti-human CD16-PE, CD3-PE, NKG2D-PE, and CD56-APC antibodies (BD
Pharmingen, San Jose, CA). Murine anti-human HLA/ABC-PE, MICA/B-PE (BD
Pharmingen), ULBP2/5/6-PE, ULBP3-PE, and ULBP-PE (R&D Systems)
antibodies were used to determine HLA and NKG2D ligand (NKG2DL) expression.
Anti-human Nectin-2/CD112 and anti-human CD155/PVR antibodies from R&D
Systems were also used to detect NK cell ligands on OS cells. Flow cytometry was
performed on a FACSCalibur cytometer (BD Biosciences) and data were analyzed
with use of FlowJo software (Tree Star, Inc., Ashland, OR).

Western blot analysis
LM7 OS cells were treated with 0.5, 1.0, or 2 µM entinostat for 48 h and
collected and lysed with RIPA lysis buffer supplemented with protease and
phosphatase

inhibitors

(Santa

Cruz

Biotechnology,

Inc.).

Total

protein
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concentration in each sample was analyzed by a Bicinchoninic acid (BCA) assay
kit (Bio-Rad Laboratories) according to the manufacturer’s instructions. Protein
samples were boiled in SDS loading buffer for 5 minutes before loading onto 10%
of SDS-poly acrylamide gels (SDS-PAGE). Samples were electrophoresed at 90
V for 2 ½ h and transferred to nitrocellulose membranes at 85 V for an hour.
Samples were then blocked in 5% milk or BSA at room temperature for 1 hour.
Expression of each individual protein was examined by overnight incubation with
primary antibody at 1:1000 ratio at 4⁰C against MICA/B, acetyl-histone3, or acetylhistone4 and visualization by horseradish peroxidase (HRP) conjugated
secondary antibody. Signal was detected after incubation with enhanced ECL
reagent (GE healthcare life sciences). Beta actin was used as loading control.

Real-time polymerase chain reaction
LM7 OS cells were treated with 0.5, 1.0, or 2 µM entinostat for 48 h. Total
RNA was isolated and purified from treated and untreated LM7 with use of Trizol
reagent (Life Technologies, Inc., Gaithersburg, MD). Reverse transcription was
performed by using the ReverseTranscription System with oligo-dT primer
(Promega Corporation, Madison, WI) according to the manufacturer’s instructions.
mRNA levels of MICA and MICB were measured by real-time polymerase chain
reaction by using iQ SYBR Green Supermix (Bio-Rad Laboratories). The PCR
reaction mixture of 25 μL was prepared by using 100 ng of reverse-transcribed
total RNA as template, 50 nM each forward and reverse primers, and 12.5 μL of
SYBR green buffer (Bio-Rad Laboratories Inc., Hercules, California). Specific
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primers

for

MICA

and

MICB

were

as

follows:

MICA,

5ʹ-

AGGGTTTCTTGCTGAGGTACA-3ʹ

(forward)

and

5ʹ-

GGTCTCTCTGTCCCATGTCTTA-3ʹ

(reverse);

MICB,

5ʹ-

TCTTCGTTACAACCTCATGGTG-3ʹ (forward), and
5ʹ-TCCCAGGTCTTAGCTCCCAG-3ʹ (reverse). Cycling conditions were 950C for 3
min, 45 cycles of 59 ͦ C annealing for 30 s, 95 ͦ C for 30 s, and 60 ͦ C for 1 min.

For the miRNA assay, total RNA was isolated and purified from cultured
cells with use of Trizol reagent. Reverse transcription was performed by using a
TagMan miRNA reverse transcription kit according to the manufacturer’s
instructions. For each 15-µL RT reaction, 7 µL RT master mix, 5 µL total RNA (5
ng), and 3 µL of RT primer were combined. The resulting cDNA was subjected to
PCR amplification with use of specific primers for Mir-20a, Mir-93, or Mir106b.

Cytotoxicity assay
NK cell cytotoxicity was measured by using a calcein release assay as
described previously (58). Briefly, 1 x 106 target cells were resuspended in 1 µM
calcein-AM diluted in DMED and incubated at 37οC for 1 h. Cells were washed
with RPMI media twice and co-cultured with ex vivo expanded NK cells in 96-well
U-bottom plates in a total volume of 200 µL in triplicate and at a ratio of 0.3125:11:10 (effector cell: target cell). Plates then were incubated at 37οC for 4 h. Calceinlabeled target cells and calcein-labeled target cells treated with 2% Tween 20 were
considered as spontaneous release and maximum release, respectively. A total of
106

100 µL of supernatant was transferred to a 96-well flat bottom plate. The plate was
read at excitation and emission wavelengths of 485 nm and 530 nm, respectively.
Percent specific lysis was calculated according to the formula [(test release −
spontaneous release) / (maximum release − spontaneous release)] × 100.

Chromatin Immunoprecipitation (CHIP)
LM7 cells were treated with 2 µM entinostat for 48 h. Chromatin
immunoprecipitation was performed by using a CHIP assay kit (Millipore,
Temecula, CA) according to the manufacturer’s instructions. Briefly, cell lysates
were treated with 1% formaldehyde to crosslink protein and DNA. Lysates were
sonicated to shear chromatin to 200-1000 bp in length and immune-precipitated
by antibodies specific to acetyl-histone H3, acetyl-histone H4, histone H3, histone
H4, or respective isotype control IgG antibodies.

MICA and MICB promoter

regions were amplified by quantitative real-time PCR using primers specific to
MICA or MICB. A 423-bp segment located at -439 upstream of the translation
initiation site of the MICA (1), as well as a 233-bp of MICA (2) located at –215 to
+18 of the gene were amplified by using the following primers: MICA (1) forward
5′-GAAGGAACAAGCCAGTG-3′,

reverse

5′-GCCAGAAGCAGGAAGACC-3′;

MICA (2) forward 5′-TTA GGC TGC GCT CCC GCG TGC TCC-3′, reverse 5′-CTC
AGC GGC TCA AGC AGT GGC CGG-3′. Likewise, a 220-bp fragment of the MICB
(1) promoter covering bases from –239 to –20 as well as a 678-bp located at MICB
(2) gene promoter were amplified by using the following primers: MICB (1) forward
5′-GTT TGG AGC TGT ACT CTC AGC TAC-3′, reverse 5′-CCC GCT CAG CGA

107

CCG CTT ATC CAG-3′; MICB (2) forward 5′ GCGACAGGGTCCAGGTCGTGCTC3′, reverse 5′-CCCTACGTCGCCACCTTC TCAGCT-3′. After normalizing the
readings to inputs, the results were presented as a ratio of acetylated histone (H3
or H4) to total histone (H3 or H4).

miRNA mimics transfection.
miRNA mimics and the negative control of miRNA mimics were transfected
into OS cells lines using Lipofectamine RNAiMAX transfection reagent (Invitrogen,
Carlsbad, CA). A total of 2 × 105 OS cells/well were seeded in a 24-well plate and
transfected with the miRNA mimics at a final concentration of 5 pmol. Cells were
collected at 24 and 48 hours and analyzed by a flow cytometry assay. Total RNAs
were isolated and purified from cells by using Trizol reagent and subjected to RTPCR and then quantitative real-time PCR.

Determination of sub-therapeutic dose of entinostat for the in vivo study
Female nu/nu mice (aged 4-6 weeks) were injected intravenously with 2 ×
106 LM7 cells suspended in 0.2 mL of PBS solution. Visible nodule formation was
confirmed 8 weeks later after euthanization. Mice then were treated with 2.5, 5, or
10 mg/kg entinostat 3 times a week for 2 weeks. At the end of treatment nodules
were removed from the lungs and total mRNAs were extracted using Trizol
reagent. MICA and MICB mRNA levels were evaluated by quantitative real-time
PCR.
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Animal model
Four- to six-week-old nu/nu mice were injected intravenously with 2× 106
LM7 cells suspended in 0.2 mL of PBS solution. About 5-6 weeks later, a few mice
were euthanized to evaluate lung micrometastasis formation. Thereafter,
treatment was started in the following four mouse treatment groups: 1) DMSO; 2)
entinostat; 3) NK cells+ DMSO; and 4) NK cells+ entinostat. Mice received 5 mg/kg
of entinostat or 200 µL of DMSO (control) by oral gavage three times a week for 5
weeks. A total of 50× 106 NK cells were injected via the tail vein twice a week for
5 weeks. A total of 12-16 mice were included in each mouse group. Mice were
euthanized after 5 weeks of treatment. The lungs were removed, and the visible
lung metastases were counted and measured. Fresh-frozen samples from the
resected lungs were prepared for further use.
In the case of using luciferase-expressing LM7 cells, nude mice were
injected via tail vein with 2 × 106 LM7-Luc cells (a gift from Dr. Gottschalk from
Baylor College of Medicine). Mice were monitored every week for micrometastasis
formation in the lung by bioluminescent imaging. When micrometastases were
observed in 75% of the mice, the mice were evenly distributed into four groups.
Treatment was initiated with DMSO, entinostat, NK cells+ DMSO, or NK cells+
entinostat for 5 weeks. Mice received 5 mg/kg of entinostat or 200 µL of DMSO
(control) by oral gavage 3 times a week for 5 weeks. A total of 50× 106 NK cells
were injected via the tail vein twice a week for 5 weeks. A total of 11-12 mice were
included in each mouse group. Before treatment and at the end of treatment the

109

tumor burden was evaluated by bioluminescent imaging using the IVIS spectrum
system (Xenogen). Mice were kept for the survival assay.
Immunohistochemistry
Paraffin-embedded

lung

tissues

were

used

for

analysis.

After

deparaffinization and rehydration of slides, antigen retrieval was performed by
using sodium citrate. To block exogenous peroxidase, slides were incubated with
3% H2O2 for 12 minutes followed by PBS supplemented with 4% fish gelatin in
PBS. Antibodies specific to MICA/B (abcam, US) was applied and left overnight at
4°C followed by incubation with horse radish peroxidase-labeled secondary
antibodies for 2 hours at room temperature. Slides were then developed with 3, 3′diaminobenzidine (DAB) as a substrate, and counterstaining was done with
hematoxylin. Negative controls were prepared in the same manner as the samples
except that they were treated with primary antibodies.

Immunofluorescence
To quantify the presence of infused NK cell in the mouse lung, 50 x 106 CMDil labeled NK cells were injected via the tail vein. At 50 min and at 24 h after NK
cell injection, the mice were euthanized and the lungs removed. The frozen
sections of the lung tissues were stained for the nucleus using Hoechst 33342
nucleic acid stain (Molecular Probes) at 1:50,000 dilution in PBS. Slides were
examined under a fluorescence microscope. Lung tissues from mice that did not
receive CM-Dil labeled NK cells were used as the controls.
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Frozen sections from our in vivo experiment were analyzed by
immunofluorescence staining for NK cells. Slides were fixed with 4% formaldehyde
for 10 minutes. Slides then were incubated with blocking solution (4% fish gelatin
in PBS) for 20 minutes at RT. Goat anti-human NKp46 antibody (10 μg/ ml) was
added (R&D System, US) and slides were incubated at 4ο C overnight. After
washing with PBS, slides were incubated with anti-goat secondary antibody for 1
hour at RT. After washing with PBS, nucleus were stained with use of Hoechst
33342 nucleic acid stain. Slides then were mounted and examined with the use of
a Zeiss Axioplan fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY)

Statistical analysis
The unpaired student t-test was used for statistical comparisons of groups.
Survival studies were analyzed with use of a Mann-Whitney rank-sum test. P
values of less than 0.05 were considered statistically significant.
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